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Abstract 
The human Mad1 protein, 35kD, is a 220 amino acid polypeptide with a short half-life 
(t1/2=15-30min), whose gene is localized on chromosome 2p12-13. The expression 
of Mad1 is tightly regulated and its synthesis can be modulated in response to 
diverse signals that control cell behavior. One example is that granulocyte colony-
stimulating factor (G-CSF) that drives differentiation of granulocytic cells induces 
mad1 expression. In general, Mad1 is well expressed in a variety of cells undergoing 
differentiating and in non-cycling terminally differentiated cells. It has been shown 
that Mad1 interferes with cell cycle progression, drives cell differentiation, prevents 
apoptosis and blocks transformation. Mad1 can regulate different aspects of cell 
behavior by modulating gene expression. At the molecular level, Mad1 acts as a 
repressive transcription factor through Mad1/Max heterodimers by binding to 5’-
CACGTG E-box DNA site and by recruiting histone deacetylase-containing 
corepressor complexes. However, little is known about the regulatory mechanisms 
that control the expression of the mad1 gene.  
 
The aims of the study were to investigate the transcriptional regulation of the mad1 
gene. In particular, we would like to: 1) identify the key regulatory elements of the 
mad1 promoter that mediate the response to G-CSF; 2) identify transcription factors 
controlling the expression of the mad1 gene; 3) investigate possible cooperations 
between the transcription factors defined; and 4) define the signal transduction 
pathways, which are relevant for G-CSF-dependent induction of mad1 gene 
expression in hematopoietic cells.  
 
In the study presented here, the following observtions were made: First, in U937 
promyelocytic cell, G-CSF-induced expression of the mad1 gene was demonstrated 
by real time PCR. This induction was sensitive to inhibition of MAP-kinases. Second, 
the -184 - +247 mad1 promoter fragment, containing part of the homology region, 
was identified as functional promoter. Althougth this fragment lacks a TATA-box it 
overlaps with a CpG-island that contains GC-boxes. In response to G-CSF, the 
region from -1282 to -796 reduces activation, whereas the region from -184 to -59 
contains G-CSF responsive elements. It appears that for this two CCAAT-boxes are 
critical. The GC-boxes are important for mad1 promoter’s activity, they are probably 
not directly relevant for the activation of the promoter in response to G-CSF/G-CSFR. 
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In addition, a possible cooperativity exists between CCAAT- and GC-boxes in the 
regulation of the human mad1 promoter. Third, both C/EBP and Sp proteins regulate 
the activity of the mad1 promoter in response to G-CSF through CCAAT- and GC-
boxes respectively. While Sp proteins bind to the mad1 promoter constitutively, 
C/EBP proteins, especially C/EBPβ, appear to play major roles in the induction of the 
mad1 gene in response to G-CSF. Fourth, STAT3 is implicated in the regulation of 
mad1 expression in an indirect way, suggesting a new cooperative mechanism with 
C/EBPβ. Finally, regarding signal transduction pathways, the data presented here 
demonstrate that four tyrosine residues (Y704, Y729, Y744 and Y764) within the 
cytoplasmic domain of the G-CSFR orchestrate the induction of mad1 expression. 
Both the JAK/STAT and the RAS/RAF/MAPK pathways are involved in the activation 
and the final signals may converge on the transcription factor C/EBPβ    t interacts 
with STAT3, supporting a CEBPβ-dependent model of the induction of mad1 
expression in response to G-CSF. 
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1 Introduction 
1.1 Myc/Max/Mad network 
The Myc/Max/Mad network of transcription factors plays pivotal roles in many cellular 
functions, including proliferation, differentiation, and apoptosis. Dysregulation of this 
network contributes to the development of human tumors and many other diseases. 
The core members of this network, including Myc family proteins, Max and Mad 
family proteins, and their biological activities will be discussed in the following.  
1.1.1 Myc proteins  
Myc (MarvelouslY Complex/Myelomonocytic tumors) proteins, including c-Myc, N-
Myc, and L-Myc, are transcriptional regulators of the basic region/helix-loop-
helix/leucine zipper (bHLHLZip) family. Since the identification of the c-myc gene as 
transforming agent of chicken retroviruses (Sheiness et al., 1978), the N-myc and L-
myc genes were discovered as amplified or highly expressed genes in the childhood 
tumor neuroblastoma (Kohl et al., 1983; Schwab et al., 1983) and in small cell lung 
cancer (Nau et al., 1985), respectively. Generally, Myc proteins, tightly controlled in 
normal cells, regulate genes that drive cell proliferation, inhibit differentiation, and 
induce apoptosis in many cell types (Nesbit et al., 1999; Grandori et al., 2000). In 
addition, Myc proteins have also been implicated in controlling many genes that 
regulate ribosome biogenesis, protein translation, genomic instability, and 
angiogenesis (Oster et al., 2002; Poortinga et al., 2004; Patel et al., 2004). Elevated 
expression of Myc proteins has been found in many tumors including breast, colon 
and gynaecological cancers, hepatocellular carcinomas and a variety of 
hematological tumors (Dang et al., 1999; Nesbit et al., 1999; Grandori et al., 2000), 
strongly indicating that Myc proteins are involved in tumorigenesis. Moreover, 
Constitutive expression of Myc in transgenic mice accelerates tumorigenesis. 
Interestingly at least in some models, tumor regression in these mice is seen when 
Myc expression is inactivated (Pelengaris and Khan, 2003; Shachaf et al., 2004). 
Together these findings demonstrate that Myc proteins are highly versatile factors 
influencing many aspects of cell behavior and their deregulated expression is closely 
linked to the occurrence and development of various tumors. 
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Structure/function analyses of Myc proteins have revealed several domains that can 
function as independent units (Figure 1-1) (Henriksson and Luscher, 1996). The 
amino terminal domain functions as a transactivation domain (TAD) and contains two 
highly conserved regulatory regions (Myc box (MB) I and II). This region is 
responsible for recruiting various transcriptional cofactors, including histone 
acetyltransferases (HAT), basal factors and ubiquitin ligases (Kim et al., 2003; 
McMahon et al., 2000). The bHLHLZip domain at the carboxy terminus of Myc is 
essential for its biological activities because it is necessary to form heterodimers with 
the bHLHLZip region of Max (Myc-associated factor x) prior to sequence-specific 
DNA binding (Blackwood and Eisenman, 1991; Luscher and Larsson, 1999). 
Myc/Max heterodimers resemble microscopic scissors, with the blades cutting into 
the major groove of the DNA double helix, allowing Myc/Max to recognize CACGTG 
DNA motifs through specific contacts made by appropriately positioned amino acids 
(Nair and Burley et al., 2003). 
 
Figure 1-1. Domain structure of members of the Myc/Max/Mad network. The known functional 
domains of different network members are shown. TAD: transactivation domain; I: Myc box I; II: Myc 
box II; R: region involved in repression; b: basic region; HLH: helix-loop-helix domain; Zip: leucine 
zipper domain; SID: mSin3-interaction domain; T-domain: T-box DNA binding domain; TRD: 
transrepression domain; P: position of known phosphorylation sites. The numbers refer to amino acids 
of the human proteins. (From Luscher, 2001) 
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In general, Myc-dependent activation involves the recruitment of multiple coactivators, 
including the mediator complex, the TRRAP adaptor protein and CBP/p300 to E-box 
elements. For example, the common transformation/transcription domain associated 
protein (TRRAP), which is part of a large complex possessing HAT activity, binds to 
the MBII motif, is recruited to Myc-regulated promoters and mediates chromatin 
remodelling. Putative dominant negative mutants of TRRAP inhibit Myc’s 
transforming activity, indicating that the interaction with TRRAP is important for Myc’s 
biological functions (Bouchard et al., 2001; Frank et al., 2003; McMahon et al., 2000). 
Likewise, CBP/p300 provides an additional example of a cofactor that is suggested to 
mediate activation by a mechanism that depends on HAT activity (Vervoorts et al., 
2003). Furthermore, INI1/hSNF5 was shown to interact with the carboxy terminus of 
Myc. hSNF5 is a key component of the SWI/SNF complex that remodels chromatin in 
an ATP-dependent manner, thereby affecting the structure and positioning of 
nucleosomes (Cheng et al., 1999; Kingston and Narlikar, 1999). It has been 
suggested that histone acetylation and ATP-dependent remodelling allows Myc/Max 
transcription factors to access promoter regions of genes and to regulate promoter 
activity. Recently, another Myc-dependent mechanism to activate target genes was 
reported. Here Myc interacts with the E3 ubiquitin ligase SCFSKP2, which recruits 
components of the AAA proteins independent of 20S (APIS) complex to E-box 
sequences (Kim et al., 2003; Von der Lehr et al., 2003). Additionally, activation of the 
cad promoter by Myc seems to correlate with phosphorylation of the CTD of Pol II, 
indicating that Myc may be involved in promoter clearance and elongation at this 
target gene and thus capable to regulate late steps in transcription (Eberhardy and 
Farnham, 2001). 
Besides its ability to activate transcription, Myc has also been demonstrated to 
repress the transcription of specific target genes (Amati et al., 2001; Grandori et al., 
2000). Two different mechanisms have been proposed for Myc-mediated repression. 
One is dependent on a transcriptional initiator (INR) element, with the consensus 
sequence YYCAYYYYY (Y is a pyrimidine base), and requires the Miz-1 (Myc-
interacting Zn-finger 1) protein. Miz-1, a zinc finger protein identified as a partner of c-
Myc, binds to the start sites of some promoters and activates their transcription 
through the INR sequence. Myc/Max heterodimers bind to Miz-1 at the INR and have 
been suggested to inhibit target gene activation by competing for CBP/p300 
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coactivator binding (Seoane et al., 2001; Staller et al., 2001). The second mechanism 
involves Myc interacting with other transcription factors, including Sp1, at enhancer 
elements to suppress gene expression. In this situation Myc seems not to require 
DNA binding or interaction with Max (Gartel and Shchors, 2003). However the 
molecular mechanism of suppression has not been resolved. 
1.1.2 Mad proteins 
The Mad family consists of four closely related proteins: Mad1, Mxi1 (Mad2), Mad3, 
and Mad4, belonging to the family of bHLHLZip transcription factors. Mad1 (Max 
dimerization protein) was originally identified as a new interaction partner in a screen 
with purified radioactively labeled Max protein as a probe on a λgt11 protein 
expression library (Ayer et al., 1993). At the same time, Mxi (Max interactor 1) was 
isolated in a yeast two hybrid screen with Max as bait (Zervos et al., 1993). Soon 
after that, Mad3, Mad4 and two additional Max partners, Mnt and Mga, were also 
identified (Hurlin et al., 1997; Hurlin et al., 1995; Hurlin et al., 1999). These Max 
partners have been proposed to function as natural antagonists of Myc, as they can 
effectively compete for interactions with Max through their bHLHLZip dimerization 
domain and generally repress, rather than activate as compared to Myc, transcription 
by binding to cognate Myc-Max DNA recognition E-box sites (Grandori et al., 2000; 
Henriksson and Luscher, 1996; Rottmann and Luscher, 2006). Therefore, a model 
was soon proposed to suggest that Myc/Max and Mad/Max complexes form a 
molecular switch involved in the regulation of the transition between different cell 
states, in which Myc/Max complexes are exchanged by antagonizing Mad/Max 
complexes, and vice versa, on responsive E-box DNA elements (Ayer and Eisenman 
1993; Ayer et al., 1993). In support of this, Myc/Max and Mad/Max complexes are 
expressed mainly in growing and in resting and differentiated cells, respectively 
(Figure 1-2). 
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Figure 1-2. Schematic summary of the different expression profiles of Myc/Max/Mad proteins 
during the different stages of the cell cycle and in differentiation.  
Repression mediated by Mad/Max is thought to antagonize the transcriptional 
activation and proliferation-promoting functions of Myc/Max heterodimers. Through 
the Sin3 interaction domain (SID), Mad proteins recruit the mSin3A and mSin3B 
corepressor complexes that contain histone deacetylase (HDAC) activity. This is 
necessary to mediate repression since it deacetylates lysine residues of the amino-
terminal tails of nucleosomal core histones H3 and H4, which leads to an increased 
interaction of the histone tails with the DNA backbone, and forms a repressive 
chromatin structure (Knoepfler and Eisenman, 1999; Schreiber-Agus and DePinho, 
1998; Sommer et al., 1997). Thus, the SID is crucial for the functions of Mad proteins 
in transcriptional repression. Indeed, deletion of the SID impairs the activity of Mad 
proteins in transformation, transactivation, cell growth inhibition, and apoptosis 
(Baudino and Cleveland et al., 2001; Grandori et al., 2000; Rottmann and Luscher, 
2006). 
1.1.3 Max proteins and others 
Max, an obligatory partner for Myc as well as Mad proteins, plays a central role in the 
Myc/Max/Mad network (Blackwood and Eisenman, 1991; Blackwood et al., 1992). 
Max can form transactivating complexes when associated with Myc but repressive 
complexes when bound to Mad (Amati et al., 1993a; Luscher, 2001). Thus Max is 
believed to function primarily as a cofactor for DNA binding by Myc and Mad proteins. 
This is consistent with its ubiquitous and constitutive expression. Comparing to the 
structure of Myc and Mad proteins, Max possesses a bHLHLZip domain but lacks an 
obvious transactivation or repression domain. Max, but neither Myc nor Mad proteins, 
can form homodimers, which bind to E-boxes (Sommer et al., 1998). However, Max 
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homodimers neither activate nor repress transcription. Nevertheless it is conceivable 
that Max/Max homodimers affect gene expression by competing with Myc/Max or 
Mad/Max complexes (Luscher, 2001). Recently, Mlx, a Max-like bHLHZip protein, 
has been shown to selectively heterodimerize with Mad1, Mad4, and Mnt, but neither 
with other Mad proteins nor with Myc or Max, leading to the hypothesis that there is a 
parallel pathway that regulates Mad activity independent of Max (Billin et al., 1999; 
Meroni et al., 2000). Furthermore, the fact that both Monodo A and WBSCR14 
interact with Mlx extends the Myc/Max/Mad network (Billion et al., 2000; Cairo et al., 
2001). Thus both Max and Mlx might be the central components of network 
subdomains that are interconnected by common interaction partners (Figure 1-3).  
 
Figure 1-3. The Myc/Max/Mad network: components, interactions and biological significance. 
While Myc/Max activates or represses transcription of target genes through different mechanisms, 
Mad/Max mainly functions as a repressor. The known interactions between different network members 
are indicated by arrows. The biological consequences of the different dimeric complexes are 
summarized. Question marks indicate that the functions associated with the relevant complexes are 
not known. (Modified from Zhou and Hurlin, 2001)  
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1.2 Structure, expression, and functions of Mad1 protein 
The Myc/Max/Mad network comprises a molecular switch that controls cell behavior 
at multiple levels and is closely linked to cell cycle progression. Deregulation of the 
cell cycle in particular has been implicated in a variety of human disorders, including 
cancer. In the following the discussion of Myc antagonists will concentrate on Mad1, 
the best understood Mad family member.   
1.2.1 Structure of Mad1 protein 
The structure of the Mad1 protein is shown in Figure 1-1. Mad1 is composed of an N-
terminal mSin3 interaction domain (SID), a centrally located bHLHLZip domain, and a 
C-terminal region (CT). The SID is essential for Mad1’s biological activities since it 
mediates the repression of transcription through the recruitment of mSin3-HDAC 
complexes (Ayer et al., 1996; Cowley et al., 2004; Sommer et al., 1997). The 
bHLHLZip domain of Mad1 is capable of forming heterodimers with Max, but not with 
Myc. However, Mad1 does not form homodimers. The bHLHLZip domain is essential 
for the functions of Mad1 proteins because it is required for the association with Max 
and for DNA binding.  Moreover, potential nuclear localization sequences (NLSs) are 
found within the loop region of the bHLH domain of Mad1, resulting in Mad1 proteins 
being restricted normally to the nucleus (Yin et al., 2001). Unlike Myc, Mad1 contains 
separable subnuclear targeting sequences, locating the protein to specific subnuclear 
speckles, where it is thought to function as a transcriptional repressor. Since deletion 
of the CT domain results in a partial reduction in repression, it is tempting to postulate 
that Mad1 may bind some cellular proteins through this region. However, the role of 
this domain has not been well determined yet (Rottmann and Luscher, 2006). 
1.2.2 Expression of Mad1 protein 
Mad1 proteins are typically well expressed in a variety of cells undergoing 
differentiating and in non-cycling terminally differentiated cells, including epidermal 
keratinocytes, polymorphonuclear leukocytes, granulosa cells, lymphocytes, and 
myeloid cells, as well as many tumor cell lines in response to various differentiation 
inducing agents (Bahram et al., 1999; Chaffin et al., 2003; Grandori et al., 2000; 
Iritani et al., 2002; Larsson et al., 1997; Werner et al., 2001). These agents can be 
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divided into three major classes: 1) cytokines, such as TGF-β1, interferon γ, 
granulocyte colony-stimulating factor (G-CSF), and tumor necrosis factor α (TNF-α); 
2) mitogens, for example, 12-O-tetradecanoylphorbol-13-acetate (TPA), 3) others, 
including activin A, vitamin D3, retinoic acid, metallic ions (Zn++).  
The mad1 gene has been mapped to human chromosome 2 at bands p12-p13 and 
mouse chromosome 6 (Edelhoff et al., 1994; Shapiro et al., 1994). The human Mad1 
protein is a 220 amino acid polypeptide with an apparent molecular weight of 35kD 
and has a high homology to the mouse protein. Mad1 has an extraordinarily short 
half-life (t1/2=15-30min), comparable to that of Myc proteins, while Max is stable 
(t1/2≥14hr). Similar to Myc, Mad1 is tightly regulated and the synthesis is rapidly 
modulated during changes in cell behavior. However, the analysis of Mad1 proteins 
has proven to be very difficult because of its low abundance and instability, a 
complication that is also true for other Mad proteins. Nonetheless, endogenous Mad1 
could be detected in differentiating hematopoietic cells in a complex with Max (Ayer 
and Eisenman, 1993; Bahram et al., 1999; Foley et al., 1998; Larsson et al., 1997; 
Sommer et al., 1998).  
Likewise, Mad4 is normally expressed in differentiating or differentiated cells, while 
Mad2 and Mad3 are present during the early differentiation programs but also in 
proliferating cells (Hurlin et al., 1995; Pulverer et al., 2000; Queva et al., 1998; Queva 
et al., 2001). The expression of Mnt and Mga are not restricted to differentiating cells 
(Hurlin et al., 1999; Pulverer et al., 2000). 
1.2.3 Functions of Mad1 
In response to extracellular signals, Mad1 regulates a wide array of distinct biological 
activities (Figure 1-4). Mad1 has been shown to interfere cell cycle progression, to 
drive cell differentiation, to prevent apoptosis and to block transformation (Luscher, 
2001; Oster et al., 2002). The working hypothesis is that Mad1 regulates a specific 
subset of target genes to stimulate separate downstream signaling cascades that 
then execute distinct biological activities (Figure 1-4). 
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Figure 1-4. Biological activities of Mad1. Mad1 proteins respond to various stimuli to regulate some 
known and many still unkown downstream target genes to exert their biological activities, especially 
associated with the control of the cell cycle, cell growth, differentiation, transformation and apoptosis. 
(Modified from Oster et al., 2002) 
Based on several lines of experimental evidence, Mad1 is suggested to be involved 
in the control of the cell cycle because of its inhibition of the G1 to S phase transition, 
as well as its regulation of the cyclin proteins (Rottmann et al., 2005). For example, 
through down-regulating the expression of cyclin D2, Mad1 blocks progression into S 
phase until late in G1 phase. On the other hand, the cell cycle arrest could be 
overcome by Cyclin E/CDK2 due to at least in part loss of binding of the repressor 
complex to Mad1 and inhibition of HDAC activity, suggesting that Mad1 function is 
regulated by cyclin proteins (Bouchard et al., 2001; Rottmann et al., 2005; Sommer 
et al., 1997). More significantly, targeted deletions of the mad1 gene support the 
notion that it functions in cell-cycle exit during terminal differentiation (Foley and 
Eisenman, 1999). Therefore, the blockade of cell cycle progression is closely linked 
to the functions of Mad1 to inhibit cell proliferation and to block transformation. It is 
known that over-expressed Mad1 overcomes the inhibition of terminal differentiation 
of cells by Myc and inhibits proliferation (Cultraro et al., 1997; Roussel et al., 1996). 
Furthermore ectopic expression of Mad1 blocks transformation of rat embryo 
fibroblasts (REF) by Myc and an activated RAS oncoprotein (Cerni et al., 1995; 
Koskinen et al., 1995; Lahoz et al., 1994). Recently, it was reported that injection of 
c-Myc/Ha-RAS transformed REF that also express Mad1ER, a chimeric Mad1-
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estrogen receptor ligand binding domain fusion protein, into syngenic rats results in 
aggressively growing tumors.  Importantly tumor growth was inhibited by treatment of 
the animals with 4-Hydroxy-Tamoxifen (OHT), which activates the Mad1ER fusion 
protein (Cerni et al., 2002). This suggests that Mad1 is able to suppress Myc/RAS-
mediated transformation under in vivo conditions. 
Inhibition of apoptosis is a potent and biologically relevant function of Mad1 in 
different cell systems and under different experimental conditions (Gehring et al., 
2000; Rottmann and Luscher, 2006). The first observation that Mad1 modulates 
apoptosis was made in mad1-/- mice. Hematopoietic cells isolated from these animals 
demonstrated increased sensitivity to apoptosis-inducing conditions (Foley et al., 
1998). In addition, myeloid precursor cells of Mad1 transgenic animals are less 
sensitive to limiting cytokine levels (Queva et al., 1998). Furthermore, microinjection 
of Mad1-expressing plasmids into cells was found to interfere with oncogene-induced 
apoptosis. Expression of Mad1 from a tetracycline-regulatable promoter resulted in 
inhibition of Fas-, TRAIL-, and UV-induced apoptosis, at least in part due to a 
reduced activation of caspase-8 (Gehring et al., 2000). Recently, the phosphatase 
and tensin homologue deleted on chromosome 10 (PTEN), a lipid phosphatase, 
which dephosphorylates phosphatidylinositol-3,4,5-triphosphate (PIP3), blocks the 
PI3K-PKB kinase pathway and leads to apoptosis (Vivanco and Sawyers, 2002), has 
been shown to be inhibited by Mad1 (Rottmann et al., unpublished data). These 
findings suggest that Mad1 prevents apoptosis at least in part through repression of 
PTEN.  
1.3 Targets and partners of Mad1 
It has bee suggested that Mad proteins function at least in part by antagonizing Myc 
through competing for identical E-box DNA binding site. Thus, Mad1/Max should 
have the same target genes as Myc/Max (Grandori et al., 2000; Luscher. 2001; 
McArthur et al., 1998). However, experimental data show that although Mad1/Max 
and Myc/Max have the identical in vitro DNA-binding specificity, they do not have 
identical target genes in vivo (Jame and Eisenman, 2002; O’Hagan et al., 2000; 
Sommer et al., 1998). While a number of bona fide Myc target genes have been 
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identified (Adhikary and Eilers, 2005; Patel et al., 2004), fewer reports have been 
published regarding Mad1 target genes.  
One well characterized Mad1 target gene is the hTERT (human telomerase reverse 
transcriptase) gene. hTERT is the enzymatic subunit of the human telomerase 
holoenzyme. Its enzymatic activity is responsible for the extension of chromosome 
end structures. The telomerase plays a crucial role in human cell senescence, 
immortalization, and carcinogenesis. Telomerase is strongly up-regulated in most 
human cancers (up to ~90%), whereas most normal and/or differentiated tissues 
have little or now detectable telomerase activity (Chiu and Harley, 1997; Meyerson, 
2000). While the oncoprotein c-Myc activates expression of hTERT at the 
transcriptional level (Greenberg et al., 1999; Kyo et al., 2000; Wu et al., 1999), Mad1 
represses the hTERT gene through binding to the proximal E-box of the hTERT 
promoter. This repressive effect of Mad1 requires an intact SID domain, which 
mediates the interaction with the corepressor mSin3 (Oh et al., 2000; Xu et al., 2001). 
Additionally, the report from Xu and co-workers provided direct evidence for a role of 
endogenous Mad1 in hTERT regulation during cell differentiation (Xu et al., 2001). 
However, studying a pair of cell lines that have the same genetic background but 
differ in telomerase activity, it has been argued that although Mad1 and c-Myc can 
modulate hTERT promoter activity when over-expressed, they are not the critical 
endogenous factors causing differential hTERT transcription in renal cell carcinoma 
cell lines (Horikawa et al., 2002). 
 
Cyclin D2, first implicated as a direct target gene of Myc, was also identified as a 
Mad1 target gene. Previously it was shown that ectopic expression of Mad1 
repressed the cyclin D2 promoter through direct binding of Mad1/Max heterodimers 
to the more distal E-box (E3) in the murine promoter, suggesting that Mad1 can 
regulate the cell cycle through modulation of cyclin D2 expression. Consistent with 
this, binding of Mad1/Max, instead of Myc/Max expressed in proliferating cells, to the 
human cyclin D2 promoter was detectable in differentiated cells in chromatin 
immunoprecipitation assays (Bouchard et al., 2001; Bouchard et al., 1999).  
The PTEN gene, a known tumor suppressor (Di Cristofano and Pandolfi, 2000; 
Vivanco and Sawyers, 2002), was identified as a target of Mad1 by performing a 
PCR-select screen using U2OS-tet-Mad1 cells (Gering et al., 2000). In support of this, 
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ChIP experiments provided evidence that Mad1 proteins bind to the PTEN proximal 
promoter in vivo, indicating that the repression of PTEN by Mad1 is direct (Rottmann et 
al., unpublished data).  
The question whether Myc and Mad1 have opposing biological functions as a result 
of contrasting action on the same genes remains unanswered. Recently, a set of 
Mad1 regulated genes has been identified utilizing cDNA microarrays (Iritani et al., 
2002). Over 80% of the genes repressed by Mad1 had been found previously to be 
induced by Myc. However several Mad1 target genes seem not to be regulated by 
Myc. In addition, the genes repressed by Myc have not been reported to be affected 
by Mad1. For example, binding of Myc/Max to the Miz1 protein leads to repression of 
the cell cycle inhibitor protein p15INK4b by disrupting the interaction of Miz1 and p300. 
This procedure appears not to be directly influenced by Mad1 protein (Staller et al., 
2001; Zhou and Hurlin, 2001). Thus, not all Myc target genes are regulated by Mad1, 
and vice versa (Rottmann and Luscher, 2006). 
Mad1 has specific interaction partners that are distinct from Myc interacting proteins. 
mSin3 is a crucial binding partner for Mad1 (Ayer et al., 1995). The Sin3 gene 
encodes a protein that contains four paired amphipathic helix (PAH) domains. The 
highly conserved domain PAH2 has been identified to interact with the SID domain of 
Mad1 both in vitro and in vivo. mSin3 serves as a protein binding platform that 
assembles an HDAC-containing repressor complex (Rottmann and Luscher, 2006). 
This complex deacetylates core histones of Mad1-dependent promoters, and by this 
exerts a potent transcriptional repression activity. Mad-member-interacting proteins 
(Mmip) are additional Mad interacting proteins. Mmips contain a RING finger and a 
ZIP domain that can dimerize with the Zip domains of all Mad family members but not 
with those of c-Myc and Max. When over-expressed, Mimps can sequester Mad1 into 
the cytoplasm, which may result in the degradation of Mad1 proteins or serve as a 
way to sequester and down-regulate its nuclear functions (Gupta et al., 1998; Yin et 
al., 1999). 
Introduction  13 
 
1.4 The G-CSF, G-CSFR and signal transduction pathways 
1.4.1 G-CSF and G-CSFR 
Granulocyte colony-stimulating factor (G-CSF) is a 20- to 25-kDa glycoprotein 
secreted by bone marrow stroma cells, macrophages, fibroblasts, and endothelia 
cells (Demetri and Griffin, 1991). Due to its biological significance in the control of cell 
behavior, including proliferation and differentiation of specific hematopoietic cells, G-
CSF is essential for the development of hematopoietic progenitor cells committed to 
the granulocyte lineage (Avalos, 1996). For example, severe neutropenia is a 
hematologic disorder characterized by an early stage maturation arrest of 
myelopoiesis in the bone marrow, leading to absolute neutrophil counts (ANC) below 
0.5 × 109/L, which results in an increased susceptibility to bacterial infections from 
early infancy. Most children die because of these infections despite antibiotic 
treatment. These findings are consistent with studies employing mice, in which an 
important role for G-CSF can also be documented. Mice with a disruption of the G-
CSF gene have been demonstrated to develop severe chronic neutropenia and to 
possess an increased susceptibility to infections (Lieschke et al., 1994). By 
administrating recombinant G-CSF to these mice, the symptoms caused by the lack 
of G-CSF can be substantially improved. Later and significantly, in clinical trials more 
than 90% of the patients with congenital neutropenia responded to recombinant 
human G-CSF treatment with an increase in ANC to more than 1.0 × 109/L. 
Importantly, all responding patients required significantly less antibiotics and fewer 
days of hospitalizations. Therefore, G-CSF is widely used to treat or prevent 
neutropenia in a variety of clinical settings since the late 1980ies (Zeidler et al., 2003). 
Two aspects of G-CSF are particularly important. First, G-CSF expands circulating 
pools of neutrophils by stimulating proliferation and maturation of myeloid progenitor 
cells, thereby ameliorating neutropenia and associated infections in the large majority 
of cases (Lehrnbecher and Welte, 2002; Welte and Boxer, 1997). Second, G-CSF 
increases the release of hematopoietic stem and progenitor cells from the bone 
marrow into the peripheral blood that can be used for transplantation purposes. 
Furthermore, G-CSF induces the mobilization of neutrophils from the bone marrow 
(Semerad et al., 2002).  
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The biological effects of G-CSF are mediated through a specific cell-surface receptor, 
the G-CSFR, which belongs to the class I cytokine receptor superfamily and forms 
homodimeric complexes upon ligand binding. The G-CSFR is expressed on 
hematopoietic progenitor cells, myeloid leukemic cells and cell lines, and mature 
neutrophils, as well as on some non-hematopoietic cell types (van de Geijn et al., 
2003). The number of G-CSFR ranges from 300-2000 per cell, and G-CSF binds to 
its receptor with a Kd of 100-500pM (Avalos, 1996). 
The G-CSFR contains a single extracellular domain, a transmembrane domain, and 
an intracellular domain (Avalos, 1996; van de Geijn et al., 2003). The extracellular 
domain consists of Ig-like domains, a cytokine receptor homologous (CRH) region 
and three fibronectin (FN)-III-like repeat domains. The Ig-like domains and CRH 
region are involved in binding of G-CSF, whereas the FN-III-like repeat domains play 
a role in stabilizing receptor dimers. The intracellular domain possesses two motifs in 
the membrane-proximal region, called box 1 and box 2, which are essential for the 
transduction of proliferation signals and a third conserved motif, named box 3 in the 
membrane-distal region, which has been implicated in the control of G-CSF-induced 
differentiation of myeloid progenitor cell lines and in the transduction of signals in 
mature neutrophils. There are four conserved tyrosine residues at positions 704, 729, 
744, and 764 within the cytoplasmic part of the human G-CSFR (equivalent to 703, 
728, 743, and 763 in the murine G-CSFR), that function as docking sites for multiple 
SH2-containing signaling proteins (Figure 1-5) (De Koning et al., 1998; Nicholson et 
al., 1995). These discrete functional elements in the G-CSFR led to the suggestion 
that multiple signaling pathways are activated by the engagement of G-CSF with the 
receptor. 
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Figure 1-5. Signal transduction pathways activated by the G-CSFR. The signaling pathways 
coupled to the G-CSFR and the contributions to the cellular response are shown on the right. 
Mechanisms that are involved in the negative regulation of the receptors are indicated on the left. 
(Modified from van de Geijn et al., 2003) 
1.4.2 Signaling pathways activated by G-CSF  
The G-CSFR lacks intrinsic tyrosine kinase activity. However the receptor interacts 
with tyrosine kinases of the JAK family. The receptor-associated cytoplasmic tyrosine 
kinases are activated in response to binding of G-CSF to the receptor and 
subsequently stimulate different signal transduction pathways, which lead to different 
cellular responses (Avalos, 1996; van de Geijn et al., 2003). JAK/STAT, 
RAS/RAF/MAPK, and PI3-kinase cascades are three major signal transduction 
pathways triggered by the G-CSF/G-CSFR and will be discussed in the following. 
The cross-talk between these different signaling transduction pathways are only 
poorly understood. 
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
signaling pathway is activated through various cytokine receptors (Rawlings et al., 
2004), especially those without an intrinsic tyrosine kinase domain. The binding of G-
CSF to its receptor leads to receptor dimerization and subsequently induces tyrosine 
phosphorylation and activation of JAK1, JAK2, and TYK2 (Nicholson et al., 1995; 
Shimoda et al., 1997; Shimoda et al., 1994), which are constitutively associated with 
the receptor.  The activated JAKs in turn phosphorylate the tyrosine residues within 
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the G-CSF receptor cytoplasmic tails, which provides docking sites for recruitment of 
STATs through interaction with the SH2 domain in STATs. For example, it has been 
suggested that STAT3 can be recruited to the phosphorylated tyrosine residues at 
positions 704 and 744 of the human G-CSFR (Ward et al., 1999). Once STATs are 
phosphorylated by JAKs, they form heterodimers or homodimers, translocate to the 
nucleus, and bind to their cognate DNA sequences to induce target gene expression 
(Ihle, 1996; Ihle et al., 1997). In the context of G-CSF/GCSFR signaling, it has been 
reported that STAT1 and STAT5 are mainly involved in regulating cell proliferation 
(Dong et al., 1998), whereas STAT3 is essential for G-CSF-induced growth arrest 
and differentiation, as well as for proliferation of myeloid progenitors (Maun et al., 
2004; McLemore et al., 2001; Shimozaki et al., 1997; Tian et al., 1996).  
In addition to the JAK/STAT signaling pathway, mitogen-activated protein kinase 
(MAPK) pathways are also activated by G-CSF. MAPK pathways are critical for cell 
growth, cell differentiation, cell cycle progression and cell death (Baumann et al., 
2001; Darley and Burnett, 1999). The MAPK family can be subdivided into three 
groups: extracellular signal-regulated kinases (ERKs), c-Jun NH2-terminal kinase 
(JNK), and p38MAPK (Morrison and Davis, 2003). The most extensively studied 
MAPK pathway is the RAS/RAF/MEK/ERK cascade. RAS is a membrane-bound 
guanosine triphosphate (GTP)/guanosine diphosphate (GDP)-binding protein that 
initiates MAPK signal transduction. The activation of RAS is mediated by adaptor 
proteins, including Shc, Grb2 and son of seven (SOS), that are recruited to the 
phosphorylated Y764 docking site of the cytoplasmic tails of the human G-CSFR. 
RAS is responsible for the activation of RAF, which in turn phosphorylates MEKs. 
The MEKs are dual-specificity kinases that can phosphorylate both serine/threonine 
and tyrosine residues on the ERKs. This results in the activation of ERKs and their 
translocation into the nucleus where they phosphorylate many transcription factors, 
including C/EBPs, that are involved in regulating gene expression (Figure 1-5) 
(Nakajima and Ihle, 2001). Activation of the JNK and p38MAPK pathways is also 
controlled via Y764 of G-CSFR, but the role of these cascades in G-CSF signaling is 
still unclear (Rausch and Marshall, 1997; Rausch and Marshall, 1999).  
The phosphatidylinositol 3’-kinase (PI3K)/protein kinase B (PKB, or AKT) pathway 
has been implicated in providing proliferation and survival signals upon activation of 
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the G-CSFR. Activation of PI3K produces phosphatidylinositol-3,4,5-triphosphate, 
which can directly bind to the pleckstrin homology (PH) domain of PKB as well as to 
kinases that activate PKB, resulting in phosphorylation of PKB (Vivanco and Sawyers, 
2002). PKB promotes cell survival through inhibition of apoptosis by phosphorylating 
and inactivating BAD and inducing Bcl-2 expression as well as controlling other 
apoptosis-associated proteins (Ahmed et al., 1997; Datta et al., 1997). This process 
requires a conserved region of the G-CSFR encompassing amino acids 682-715 
(Figure 1-5) (Dong and Larner 2000; Hermans et al., 2003; Hunter and Avalos, 1998). 
1.4.3 Negative regulation of the G-CSF signaling 
The activation of distinct signaling pathways by G-CSF/G-CSFR also results in the 
regulation of genes and proteins that repress G-CSFR signaling (Figure 1-5). Ample 
evidence indicates that the suppressors of cytokine signaling (SOCS) proteins down-
regulate G-CSFR signaling. SOCS proteins, including SOCS1 through SOCS7 and 
CIS, have been described as a new family of inhibitors of cytokine signal transduction 
(Naka et al., 1997; Starr et al., 1997). Of those CIS, SOCS1, SOCS2 and SOCS3 are 
the best characterized (Alexander, 2002; Alexander and Hilton, 2004; Kubo et al., 
2003). SOCS proteins have a central SH2 domain, an N-terminal domain of variable 
length and sequence, and a C-terminal 40-amino-acid module called SOCS box. Of 
these SOCS proteins, SOCS3 expression is strongly and rapidly induced in primary 
myeloid cells when stimulated by G-CSF (Hortner et al., 2002). SOCS3 binds 
selectively to the human G-CSFR at tyrosine 729 when this residue is 
phosphorylated (pY729) (Hortner et al., 2002) and in turn potently inhibits G-CSFR-
mediated STAT activation, suggesting that SOCS3 is a critical negative regulator of 
G-CSF receptor signaling (Croker et al., 2004; Hortner et al., 2002). In addition, the 
SOCS box of the SOCS proteins is thought to be involved in protein degradation via 
the ubiquitin-proteasome pathway (Zhang et al., 1999). 
Additionally, phosphatases and proteasome-mediated degradation are involved in 
the down-regulation of G-CSF signaling (van de Geijn et al., 2003). For example, 
upon binding of G-CSF to the G-CSFR, the SH2 domain-containing protein tyrosine 
phosphatase-1 (SHP-1) is activated and recruited to the distal region of cytoplasmic 
region of the G-CSFR and then acts as a negative regulator. In addition, SH2-
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containing inositol phosphatase (SHIP) protein, another phosphatase, can be 
activated by binding to phosphorylated Y764 of the G-CSFR and negatively regulates 
the growth factor-mediated PI-3K/PKB activation and survival of myeloid cells (Hunter 
and Avalos 1998; Liu et al., 1999). Together these studies reveal a multitude of 
different signal transduction pathways that are controlled by G-CSF/G-CSFR and that 
mediate a broad spectrum of activities involved in regulating cell behavior.  
1.5 Transcription factors in granulopoiesis  
It is known that granulopoiesis involves the coordinated action of various cytokines 
and transcription factors (Friedman et al., 2002; Lotem and Sachs, 2002; Zhu and 
Emerson, 2002). Of the cytokines affecting granulopoiesis, G-CSF stimulates the 
proliferation, differentiation and survival of granulocyte precursors that are committed 
to the neutrophil lineage, whereas IL-3 mainly supports the genesis of basophils, 
while the combination of IL-3 and GM-CSF affects differentiation of eosinophils. Of 
the transcription factors that are closely associated with G-CSFR signaling, the 
proteins of the C/EBP family, SP proteins, STATs, PU.1, and c-Myb will be discussed 
in the following. 
1.5.1 C/EBPs 
The CCAAT/enhancer-binding proteins (C/EBPs) encompass a family of basic 
region-leucine zipper transcription factors, including C/EBPα, -β, -γ, -δ, - ε, and -ζ 
(Lekstrom-Himes and Xanthopoulos, 1998). With structural as well as functional 
homologies, C/EBPs play an important role in the growth and differentiation of many 
tissues and cell types both in vitro and in vivo (Lekstrom-Himes and Xanthopoulos, 
1998; Nerlov, 2004). C/EBPs homo- and hetero-dimerize via their C-terminal leucine 
zipper domains, bind consensus DNA sequence elements (5’ -CCAAT-3’, so called 
CCAAT-boxes) as dimers via the adjacent basic region and exert their transcriptional 
functions via N-terminal regions (Figure 1-6) (Tenen et al., 1997; Ward et al., 2000).  
C/EBPα, the founding member of the C/EBP family, was originally isolated as an 
activator of liver-specific transcription (Costa et al., 1988) and has been most 
extensively studied. Substantial evidence has shown that C/EBPα?is a transcription 
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factor, which coordinates cellular differentiation with growth arrest, especially in the 
process of granulopoiesis but also in many other tissues (Nerlov, 2004; Tenen, 2003; 
Tenen et al., 1997). For instance, conditional expression of C/EBPα?in bipotential 
myeloid cells induces granulopoiesis and blocks monocyte differentiation (Radomska 
et al., 1998), whereas loss of C/EBPα?results in the absence of granulocytes but 
retains monocytes, lymphocytes and erythroid cell differentiation (Zhang et al., 1997). 
In support of this, C/EBPα?is expressed in myeloblast progenitors and granulocytes, 
but not monocytes.  In addition, a number of granulocyte-specific genes, including G-
CSFR (Smith et al., 1996), neutrophil elastase (Oelgeschlager, et al., 1996), 
myeloperoxidase (Ford et al., 1996), lactorferrin (Khanna-Gupta, et al., 2000) and 
PU.1 (Wang et al., 1999), can be regulated by C/EBPα. Several mechanisms have 
been proposed to explain how C/EBPα exerts its transcriptional function. It has been 
suggested that the transactivation domain located in the N-terminal region of C/EBPα 
directly or indirectly contacts TBP/TFIIB (Nerlov and Ziff, 1995), binds to CBP/p300 
(Kovacs et al., 2003; Schwartz et al., 2003), and/or recruits SWI/SNF (Iakova et al., 
2003; Mueller et al., 2004; Pedersen et al., 2001) to activate lineage-specific genes. 
In addition C/EBPα?mediates repression of E2F complexes and down-regulates c-
Myc, which enhances granulocyte differentiation (Iakova et al., 2003; Johansen et al., 
2001). Furthermore, C/EBPα?up-regulates p21WAF1 (Timchenko et al., 1997) and 
interacts with and directly inhibits the cyclin-dependent kinases CDK2/4 (Wang et al., 
2001), resulting in cell growth arrest. Together these findings strongly suggest that 
C/EBPα?engages with multiple targets to mediate cell cycle exit and differentiation of 
cells. 
Introduction  20 
 
 
Figure 1-6. A comparison of the structural features and expression patterns of C/EBPα, 
C/EBPβ , and C/EBPε. A) The locations of characterized functional domains within the three major 
members of C/EBP family are summarized. Information regarding the interaction domains of the 
indicated proteins is outlined. TE: transcription element; BR-LZ: basic region-leucine zipper; RD: 
regulatory domain; TAD: transactivation domain. B) The expression patterns of C/EBPα, C/EBPβ, and 
C/EBPε are shown for the differentiation of myeloid cells. (Modified from Mo et al., 2004; Nerlov, 2004) 
Like C/EBPα??C/EBPβ??C/EBPδ??and?C/EBPε are also expressed in myeloblastic 
cells and induce granulocytic differentiation (Nakajima and Ihle, 2001; Wang and 
Friedman, 2002). C/EBPγ?and?C/EBPζ?are ubiquitously expressed proteins, which 
lack a transactivation domain. These proteins can dimerize with other C/EBPs and 
interfere with their activities. Among the C/EBP proteins, C/EBPβ? is of special 
interest because its expression can be activated by lipopolysaccharide (LPS), IL-6, 
IL-1, and dexamethasone. In addition C/EBPβ can enhance the production of 
inflammatory cytokines, such as IL-6, indicating a role in the mediation of an 
inflammatory response (Poli, 1998). Furthermore, changes in C/EBPβ-
phosphorylation lead to an alteration of its conformation that is associated with a 
Introduction  21 
 
switch between a suppressor and an activator form of the protein. This change in 
phosphorylation occurs in response to extracellular stimuli, including receptor 
tyrosine kinase (RTK) signaling and RAS-MAPK pathway signaling (Kowenz-Leutz et 
al., 1994). Recently, it has been demonstrated that the SWI/SNF and the Mediator 
complex are recruited by C/EBPβ, further extending the mechanistical possibilities of 
C/EBPβ in regulating gene transcription (Kowenz-Leutz and Leutz, 1999; Mo et al., 
2004). 
The similar expression patterns of several C/EBPs in myeloid cells indicate that the 
family members might compensate in vivo for each other. For example, C/EBPβ?has 
been suggested to compensate for the loss of C/EBPα? in hepatocytes and 
granulocytes in vivo (Chen et al., 2000; Jones et al., 2002). Additionally, C/EBP 
proteins can interact with a number of other transcription factors, including Sp1 (Lee 
et al., 1997), PU.1 (Nagulapalli et al., 1995), c-Myb (Tahirov et al., 2002), NF-κB and 
Rel (Diehl and Hannink, 1994; Stein et al., 1993), members of the CREB/ATF family 
(Tsukada et al., 1994), retinoblastoma protein (Rb) (Chen et al., 1995), and members 
of the Fos/Jun leucine zipper family (Hsu et al., 1994), indicating that C/EBP proteins 
may cooperate with these different transcription factors. Together these findings offer 
a multitude of possibilities how C/EBP proteins regulate gene transcription. 
1.5.2 Sp proteins 
The Sp/KLF family contains at least twenty identified members, including specificity 
proteins (Sp) (Sp1, Sp2, Sp3 and Sp4), and numerous Krueppel-like factors (KLF) 
(Black et al., 2001; Dang et al., 2000). Sp proteins share similar structural features 
(Figure 1-7) (Suske, 1999). Near the C-terminus exists a highly conserved three-zinc-
finger DNA-binding domain, whereas serine/threonine- and glutamine-rich domains 
lie in the N-terminal two-thirds of the proteins. Although little is known about Sp2 and 
Sp4, Sp1 and Sp3 have been studied extensively. Both Sp1 and Sp3 are ubiquitously 
expressed transcription factors, with binding site specificities and expression patterns 
being quite similar, leading to the notion that both have quite similar functions 
(Samson and Wong, 2002; Suske, 1999;). However, the physiological roles of Sp1 
and Sp3 appear to be significantly different since Sp3- and Sp1-deficient mice exhibit 
different phenotypes (Bouwman et al., 2000; Marin et al., 1997). Generally, Sp3 acts 
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as both a repressor and an activator of transcription. Posttranslational modifications, 
including acetylation and sumoylation, may determine whether Sp3 functions as an 
activator or a repressor. For example, it has been reported that Sp3 activity is 
repressed by SUMO-1 modification. Removal of SUMO-1 from Sp3 by mutation of 
the SUMO acceptor lysines or expression of the SUMO-1 protease (SuPr-1) converts 
Sp3 into a strong activator, which may be due to the acetylation of the same lysine 
residue through CBP and p300. Meanwhile, covalent attachment of SUMO-1 to Sp3 
by gene fusion is sufficient to convert Sp3 into a repressor again (Braun et al., 2001; 
Ross et al., 2002; Sapetschnig et al., 2002). 
 
Figure 1-7. Structural features of Sp proteins. The regions of the proteins rich in glutamine (Q) and 
serine/threonine (S/T) are indicated in red and in yellow, respectively. DNA-binding domains, 
consisting of three zinc fingers, are indicated in green. The A, B, C and D domains contribute to the 
transcriptional properties and to the regulation of Sp proteins. (From Suske, 1999) 
Sp1 has been defined as a ‘basal’ transcription factor since its initial discovery. In 
general, Sp1 functions as an activating transcription factor because Sp1 binds to and 
stimulates gene transcription through GC-boxes (GGGGCGGGG) and related 
GT/CACCC-boxes (GGTGTGGGG). In addition, Sp1 physically interacts with TFIID 
through TAFs, specifically human TAFII130, TAFII55 and Drosophila TAFII110 
(Samson and Wong, 2002), facilitates binding of TFIID to promoters that lack a TATA 
box, which, in turn, recruits the RNA polymerase II (Pol II) transcription machinery. 
Furthermore, Sp1 probably also functions as a negative transcription factor. For 
example, over-expressed Sp1 in rat hepatocytes leads to a decrease in FAS-
promoter activity (Fukada et al., 1997). Recently, Sp1 has been shown to interact 
with HDACs and to recruit HDACs to the hTERT promoter, resulting in the localized 
deacetylation of nucleosomal histones and transcriptional silencing of the gene in 
normal human somatic cells (Won et al 2002). Furthermore, various signal 
transduction cascades that are regulated in response to a multitude of signals 
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converge onto Sp1. Indeed it can be phosphorylated by numerous kinases, including 
Ca2+-calmodulin-dependent kinases (CamKs), protein kinases CK1 and CK2, protein 
kinases (PK) A and C, DNA-dependent protein kinase (DNA-PK), and ERK 1/2 
(Armstrong et al., 1997; Benasciutti et al., 2004; Sohm et al., 1999; Zheng et al., 
2000), and dephosphorylated by PP2A and PP1 (Cieslik et al., 1999; Daniel et al., 
1996). Besides phosphorylation, Sp1 is glycosylated, which protects it from 
proteasomal degradation (Han and Kudlow, 1997). Thus, Sp1 is postulated to be a 
key mediator of different signaling pathways in the regulation of gene transcription. It 
is worth pointing out that the role of Sp1 appears to be particularly diverse, with both 
positive and negative effects depending on the promoter.  
1.5.3 STATs 
Signal transducer and activator of transcription (STAT) proteins are a family of 
cytoplasmic transcription factors that convey signals from cytokine and growth factor 
receptors to the nucleus. STATs are involved in regulating many genes whose 
products control fundamental biological processes, including cell proliferation, 
differentiation, apoptosis, angiogenesis and immune responses (Levy and Darnell, 
2002; Yu and Jove, 2004). 
STATs, normally localized in the cytoplasm, have several conserved domains that 
are critical for their functions, including a coiled-coil domain, a DNA binding domain, a 
Src-homology 2 (SH2) domain and a transactivation domain. The coiled-coil domain 
is involved in the interaction with regulatory proteins and other transcription factors. 
The DNA binding domain can bind directly to the consensus core sequence TTN4-6AA. 
The SH2 domain supports the reciprocal interactions between STAT monomers upon 
tyrosine phosphorylation within the transactivation domain. This domain contains an 
additional site of serine phosphorylation that, together with the tyrosine 
phosphorylation, is required for the binding of STATs to DNA and is involved in the 
transcriptional activation of target genes through recruiting cofactors, such as histone 
acetyltransferases (Figure 1-8) (Benekli et al., 2003). 
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Figure 1-8. The STAT family of proteins. The major structural features of the STAT proteins are 
shown. The details have been explained in the context. DBD: DNA binding domain; SH2: SRC-
homology domain 2; Y: tyrosine; S: serine; p: phosphorylation site; N: amino terminus; C: carboxyl 
terminus. (Modified from Yu and Jove, 2004) 
STATs can be regulated by different protein modifications, by the PIAS family 
proteins, and by protein tyrosine phosphatases (PTPs) (Shuai and Liu, 2003). The 
post-translational modifications of STAT proteins include phosphorylation, 
methylation, acetylation, ubiquitylation, and sumoylation. Of these different 
modifications, tyrosine phosphorylation is most important. After receptor stimulation, 
STATs are usually tyrosine phosphorylated on a single conserved residue, which is 
required for protein dimerization, nuclear translocation and DNA binding (Schindler 
and Darnell, 1995). The activity of STAT proteins can also be regulated by homo- 
and hetero-dimerization formed by the different members of the family or by STAT 
splice variants that can act as dominant negative STATs (Darnell et al., 1997; 
Henriksen et al., 2002).  
STAT proteins, particularly STAT3 and the STAT5, play a critical role in governing 
signal transduction in cytokine-induced myelopoiesis, initiated by G-CSF, GM-CSF, 
EPO, TPO, IL-3 and IL-5 (Coffer et al., 2000; Smithgall et al., 2000). In the case of 
STAT3, dominant negative STAT3 mutants including STAT3F (the tyrosine residue at 
705 of STAT3 is replaced by phenylalanine) and STAT3D (the glutamic acid residues 
at 434 and 435 of STAT3 are replaced by alanines), prevented G-CSF-induced 
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neutrophils differentiation in murine myeloid LGM-1 cells, but cell proliferation was 
not impaired (Shimozaki et al., 1997). Furthermore, a targeted mutation of the G-
CSFR (termed d715F), which is generated by deleting the distal 98 amino acids of 
the G-CSFR and by mutating the sole remaining cytoplasmic tyrosine (Y704) into 
phenylalanine, abolishes G-CSF-dependent STAT3 activation and leads to severe 
neutropenia with an accumulation of immature myeloid precursors in the bone 
marrow. Expression of a constitutively active form of STAT3 in d715F progenitors 
nearly completely rescues the neutropenia, whereas expression of a dominant-
negative form of STAT3 in wild-type progenitors results in impaired G-CSF-induced 
proliferation and differentiation of neutrophils (McLemore et al., 2001). These data 
support a crucial role for STAT3 in G-CSF-driven granulopoiesis. However, it has 
also been suggested that STAT3-independent granulopoiesis exists because STAT3 
null bone marrow progenitors display mature effector functions (Lee et al., 2002). So 
the exact role of STAT3 in the regulation of granulopoiesis still remains to be clarified. 
Deregulation of STAT activation, particularly STAT3 and STAT5, has been 
demonstrated to be closely involved in a variety of human solid tumors and blood 
malignancies (Yu and Jove, 2004). Firstly, evidence shows that constitutively 
activated STATs are tightly associated with oncoproteins including Src or that STATs 
are mutated in tumors, one example being STAT3C (Bromberg et al., 1999; Turkson 
et al., 1998). Secondly, the expression of genes that promote cell cycle progression 
or block apoptosis, including cyclin D1 and cyclin D2, BCL-XL, MCL1 and survivin, are 
up-regulated by STAT proteins, whereas that of tumor suppressor genes, such as 
p53, is negatively regulated. Thirdly, STAT3 enhances the expression of vascular 
endothelial growth factor (VEGF) and indirectly leads to angiogenesis, which is 
necessary for the development of tumors (Niu et al., 2002; Wei et al., 2003). Thus, 
STAT proteins might be potential targets for cancer therapy in the future. 
1.5.4 PU.1 
PU.1, a member of the Ets transcription factor family, is expressed at highest levels 
in myeloid and B cells, but not in T cells (Smith et al., 1996; Tenen et al., 1997). PU.1 
contains an N-terminal transactivation region, a downstream PEST domain, and a 
carboxy-terminal DNA-binding domain (Fisher et al., 1998). It can bind to purine-rich 
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sequences (5′-GGAA-3′), named PU boxes, and serves as a tethering factor to 
recruit the basal transcription machinery to TATA-less myeloid promoters, and act as 
a weak transactivator. PU.1 has been shown to cooperate with other transcription 
factors, such as C/EBPs (Smith et al., 1996) and c-Jun (Bassuk and Leiden, 1995), in 
myeloid gene regulation. PU.1 also interacts with a variety of other proteins, including 
Rb (Weintraub et al., 1995), TBP (Hagemeier et al., 1993), and NF-EM45 (Eisenbeis 
et al., 1993). Together PU.1 can function as an important regulator of myeloid 
development. However, the functional significance of the interaction with different 
proteins has to be defined in more detail. 
1.5.5 c-Myb 
The proto-oncoprotein c-Myb functions as both a transcriptional activator and 
repressor. It has three imperfect 50-52 amino acid N-terminal repeats, R1, R2, and 
R3. The later two mediate binding to the consensus DNA sequence 5’-
(C/T)AAC(G/T)-3’. Myb possesses a central transactivation domain and a negative 
regulatory domain containing an EVES motif near its C-terminus (Friedman, 2002; 
Ward et al., 2000). c-Myb is mainly expressed in immature myeloid, lymphoid, and 
erythoid cells. In agreement with this, gene disruption of c-Myb in mice results in the 
lack of all hematopoietic lineages except the megakaryocytic branch (Mucenski et al., 
1991), indicating its biological significance in hematopoiesis. In addition, expression 
of c-Myb in 32Dcl3 cells allows G-CSF to induce expression of myeloperoxidase, an 
early differentiation marker, but prevents growth arrest and blocks the expression of 
late differentiation marker such as lactoferrin (Bies et al., 1995). Finally, c-Myb can 
interact with the core binding factor (CBF), a member of the AML1 family of 
transcription factors (Hernandez-Munain et al., 1994), PU.1 and C/EBPs 
(Oelgeschlager et al., 1996). Recently, it has been suggested that the conversion 
between activator and repressor functions may be dependent on the subunit 
composition of the Myb complex, which favors either coactivator or corepressor 
interactions. For example, the E2F1/Myb complex may preferentially promote 
activation of both transcription and replication by recruiting histone acetyltransferases, 
i.e. CBP, while the E2F2/Myb complex acts through recruitment of the histone 
deacetylases, such as HDAC1, to negatively regulates promoter activity (Lewis et al., 
2004; Nomura et al., 2004). However, what causes Myb to interact selectively with 
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coactivators or corepressors remains to be determined. 
1.6 Aim of the study 
G-CSF plays an important role in the regulation of proliferation, differentiation, and 
survival of myeloid cells through the interaction with G-CSFR. The signal pathways 
triggered by G-CSF/G-CSFR converge on a set of transcription factors, which are the 
final switches that activate and/or repress specific genes that ultimately lead to 
different cell behavior. Our previous data have shown that the Mad1 protein, 
preferentially expressed in hematopoietic cells, can be induced by several 
differentiation signals, such as vitamin D3 and retinoic acid. These observations 
indicate that Mad1 might be a critical regulator of the differentiation process of 
myeloid cells, especially during granulopoiesis. In this thesis, U937 and HL60 cells 
and primary myeloid progenitors are used to investigate whether G-CSF induces the 
expression of the mad1 gene. 
As an antagonist of Myc proteins, Mad1 is of particular interest because of the 
contrary functions in the cell behavior. Almost all biological activities of Mad1 protein 
are tightly linked to its role as a transcriptional repressor, however, the regulation of 
Mad1 expression is still far from being understood. Thus, this study focuses on the 
characterization of the mad1 promoter and the mechanisms involved in its regulation, 
especially at the transcriptional level. In particular, 1) to identify the key regulatory 
elements of the mad1 promoter in response to G-CSF; 2) to identify transcription 
factors controlling the expression of the mad1 gene; 3) to investigate possible 
cooperations between the transcription factors defined; and 4) to define the signal 
transduction pathways relevant for G-CSF-dependent activation of mad1 expression 
in hematopoiesis cells. Providing answers to those questions would help to elucidate 
the mechanisms of the regulation of the mad1 gene in more detail, and probably, to 
give insight into the roles it might play in diseases.  
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2 Results 
2.1 mad1 expression in different cell lines in response to G-CSF  and to TPA 
The mad1 gene is activated in human promyelocytes upon induction of differentiation. 
The promyelocytic cell lines U937 and HL60 have been used as models to study 
monocytic and granulocytic differentiation. In order to analyze whether the mad1 
gene is regulated by G-CSF, the induction of mad1 expression in these cell lines and 
in primary myeloid progenitors was examined. Other stimuli, including phorbolester 
TPA and cytokines such as IL-6 and MIF have been tested as well. 
To investigate the expression of the mad1 gene during differentiation U937 cells 
were treated with G-CSF. The induction of mad1 expression in response to TPA was 
used as positive control. Total RNA was isolated from the treated cells at different 
time points and reverse transcription was performed to obtain cDNA. The relative 
mad1 mRNA levels were examined using real time quantitative PCR. Whereas the 
expression of mad1 was increasing during the time course from 1 h to 6 h after 
addition of TPA, an increase in mad1 mRNA was evident in some experiments 
already 30 min after G-CSF treatment and peaked between 1 h and 2 h (Figure 2-1A, 
B). The effect of G-CSF was less strong than that of TPA. It should be noted that the 
U937 cells still not differentiate in response to G-CSF. Nevertheless some early 
differentiation markers are transiently induced.  The induction of mad1 mRNA was 
also observed in the presence of cycloheximide (Figure 2-1B), suggesting that mad1 
expression regulated by G-CSF is independent of de novo protein synthesis. In 
addition, G-CSF was also able to transiently induce mad1 expression in HL60 cells 
(Figure 2-1C). To address whether the mad1 gene was regulated by G-CSF in 
primary cells, cord blood derived CD34+ cells were expanded in the presence of FH3 
ligand, hyper-IL-6, TPO and SCF for two weeks. Then the cells were washed and 
stimulated by G-CSF. This resulted in a rapid but modest activation of mad1 
expression as measured by real time PCR (Figure 2-1D). A very similar finding was 
also obtained by using IL-6, but not upon stimulation by macrophage inhibitory factor 
(MIF) (data not shown). Taken together, these data indicate that mad1 expression 
can be regulated by G-CSF and is independent of de novo protein synthesis in 
different cellular contexts. 
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Figure 2-1. Induction of mad1 gene expression by G-CSF in myeloid cells. 
A) Kinetics of mad1 expression in U397 cell line. The cells were stimulated with G-CSF (10 ng/ml) and 
TPA (1.6 x 10-8 M) for the times indicated. Total RNA was isolated and analyzed by quantitative RT-
PCR with a specific probe for the mad1 gene (target gene) and the β-glucuronidase gene 
(endogenous control gene). The quantification was performed using the comparative CT method 
according to the protocol for TaqMan 7700. B) G-CSF-induced mad1 expression is independent of 
new protein synthesis. After pre-treatment with cycloheximide (25 µM) for 40 min, the U937 cells were 
stimulated with G-CSF (10 ng/ml) for the time indicated. C) Kinetics of mad1 expression in HL60 cell 
line. The cells were treated with G-CSF (10 ng/ml) and TPA (1.6 x 10-8 M) as indicated. The relative 
expression of the mad1 gene was obtained as described in panel A. D) Kinetics of mad1 expression in 
CD34+ primary cells. The cells were treated as described in the right panel. The relative expression of 
mad1 gene was analysed as described in panel A. 
2.2 Cis-elements involved in the regulation of the mad1 promoter  
Based on our previous work, the putative human mad1 promoter was cloned and 
analyzed. The mad1 gene spans over 23 kbp and has 6 exons. Comparing the 
sequences 5’ of the coding region between human, and mouse, a 400bp region with 
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high homology (HR) was identified (Figure 2-2). This region might overlap with the 
promoter. The HR between rat and mouse is also very similar (data not shown). 
Indeed primer extension analysis identified two transcriptional start sites, one being 
located within the HR (K. Eckert, unpublished observation) (Figure 2-2). The putative 
mad1 promoter is TATA-less with several non-typical initiator elements, 4 multiple 
start site element downstream (MED) sequences and no obvious down stream core 
promoter element (DPE). Importantly, there are several potential binding sites for 
different transcription factors within the HR, including sites for C/EBP, Sp, STAT, c-
Myb and PU.1 (Figure 2-2), suggesting that these transcription factors might be 
involved in the regulation of expression of the mad1 gene. To define where the mad1 
promoter is located and to determine important regulatory regions involved in the 
control of mad1 expression, different reporter gene constructs were generated. 
These constructs were examined by using transient transfection assays. For the 
numbering of the nucleotides, the start site of transcription in the HR was set as +1 
(Fig 2-2). 
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Figure 2-2. The conserved region of the mad1 promoter. 
The 400 bp high homology regions (HR) of the putative mad1 promoter of human (hu) and mouse (mu) 
are shown. The HR is characterized by a high GC content (61% GC over the 400 bp region). Potential 
transcription factor binding sites are boxed and color coded. The two mapped transcriptional start sites 
are indicated by blue triangles. 
2.2.1 Identification of the mad1 promoter and regulatory regions  
A fragment of 1529bp (-1282 - +247) of the putative mad1 promoter, containing the 
HR, was cloned into the pGL2 firefly luciferase reporter gene plasmid resulting in -
1282 mad1 promoter. This construct, unlike pGL2, displayed significant luciferase 
activity when transiently transfected into cells (Figure 2-3). To address whether the -
1282 mad1 promoter was responsive to G-CSF, the construct was transfected 
transiently into rabbit RK13 cells. The -1282 mad1 promoter was stimulated 
moderately (about 3 fold) by G-CSF (Figure 2-3). To determine the G-CSF-
responsive promoter regions, deletion mutants were generated and analyzed in 
reporter gene assay (Figure 2-3). The -795 mad1 promoter, lacking the 5’ ~500 bp of 
the mad1 promoter, was activated about 10 fold in response to G-CSF/G-CSFR. 
Further deletions of 5’ regions retained high G-CSF/G-CSFR responsiveness. The -
184 mad1 promoter fragment revealed the highest level of activation (roughly 17 fold), 
suggesting that this contains the mad1 promoter and important regulatory elements 
that indicate the G-CSF response. Deletion of a further 126 bps (resulting in -58 
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mad1 promoter) reduced and deletion beyond the start site of transcription abolished 
the G-CSF/G-CSFR response. Also these fragments showed low basal activity. A 
reporter gene construct with the isolated homology region of the mad1 promoter (-
385 - +25 mad1 promoter fragment) showed an intermediate level (about 5 fold) of 
activity upon stimulation with G-CSF/G-CSFR (Figure 2-3B), which was similar to that 
of -1282 mad1 promoter, suggesting that the homology region features the promoter 
activity. Together the findings described above suggest that 1) the -184 - +247 mad1 
promoter, containing part of the homology region, had the highest promoter activity, 
indicating that the conserved region was functionally relevant and this fragment might 
be the promoter; 2) a promoter region (from -1282 to -796) inhibited the G-CSF/G-
CSFR-mediated activation of the mad1 promoter while a segment in the homology 
region (from -184 to -59) mediated activation by G-CSF/G-CSFR. This leads to the 
notion that there is a negative and a positive regulatory region within the -1282 - +247 
human mad1 promoter.  
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Figure 2-3. Characterization of the mad1 promoter.  
A) Schematic representation of reporter gene constructs used in transient transfections. The 
stimulation of individual reporter gene constructs by G-CSF/G-CSFR is shown on the right and taken 
from panel B. The red box (-1282 to -794) and the blue box (-184 to –59) define negative and positive 
regulatory regions, respectively, of the mad1 promoter. B) The indicacted mad1 promotor constructs 
were co-transfected with human G-CSFR. After transfection, the cells were stimulated with G-CSF (10 
ng/ml) for 6 h and then harvested for luciferase assays. The relative luciferase activities of the different 
reporter constructs were normalized to the β-galactosidase activities. The results represent the mean 
± S.E. of three independent transfection experiments performed in triplicates. 
To determine whether the region from -184 to -59 is a bona fide positive regulatory 
element through which G-CSF-dependent signals activate the mad1 promoter, this 
portion was cloned upstream of the minimal thymidine kinase promoter driving the 
luciferase gene (mintk-luc). In this setting it can be tested whether a DNA fragment 
possesses enhancer function. Thus whether -184 to -59-mintk-luc was responsive to 
G-CSF/G-CSFR was investigated. As shown in Figure 2-4, the addition of the -184 to 
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-59 fragment showed little enhancer activity in the absence of a G-CSF signal. 
However, the activity of the mintk promoter with the region from -184 to -59 was 
strongly enhanced by stimulation with G-CSF/G-CSFR, while the empty mintk 
promoter was not stimulated. Thus, the region from -184 to –59 has low basic 
enhancer activity but, most importantly, is critical to mediate the inducibility by G-
CSF/G-CSFR. Therefore the -184 to -59 fragment is referred to as the G-CSF-
response element in the following. Further studies will focus on the -184 - +247 mad1 
promoter, with special emphasis on the G-CSF-response element. In addition 
possible transcription factor binding sites within this element will also be examined. 
 
Figure 2-4. Identification of the G-CSF-response element within the mad1 promoter. 
The indicacted promotor constructs were co-transfected with human G-CSFR into RK13 cells. -184 - -
59-mintk-luc is the reporter construct with the portion from –184 to –59 of human mad1 promoter; 
mintk was used as negative control. The reporter assays were performed as described in the legend to 
Figure 2-3. The results represent the mean ± S.E. of two independent transfection experiments with 
triplicate samples. 
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2.2.2 The activation of mad1 promoter in response to G-CSF is G-CSFR-
dependent 
In order to determine whether the G-CSFR is necessary for the expression of the 
mad1 promoter, the human G-CSFR was expressed in RK13 cells. These cells do 
not respond to human G-CSF. As shown in the figure 2-5, in the absence of the G-
CSFR, the -184 - +247 mad1 promoter fragment could not be activated by G-CSF. 
Co-expression of the receptor resulted in a small activation of mad1 reporter, 
probably due to autoactivation of the over-expressed receptor. In the presence of 
both G-CSF and G-CSFR, significant enhancement of the effect was achieved. 
Whereas co-transfection with 0.02 µg of the human G-CSFR expression plasmid only 
slightly increased promoter activity (about 2 fold), co-transfection with 0.5 µg resulted 
in a robust activation of the mad1 reporter (roughly 7 fold). Thus, these findings 
suggest that the presence of the G-CSFR is required for the expression of mad1 
reporter gene. 
 
Figure 2-5. G-CSF/G-CSFR-dependent activation of the mad1 promoter in RK13 cells. 
 The -184 - +247 mad1 promoter fragment luciferase reporter gene was co-transfected with different 
amounts of plasmids encoding the human G-CSFR as indicated into RK13 cells. The reporter assays 
were performed as described in the legend to Figure 2-3. The results represent the mean ± S.E. of two 
independent transfection experiments with triplicate samples. 
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2.2.3 Role of C/EBP binding sites within the G-CSF-response element 
Two CCAAT-boxes are localized within the mad1 promoter region (-184 - +247 mad1 
promoter fragment) that may function as potential C/EBP binding sites. The distal 
C/EBP binding site is located at -113 to -109 (referred to as CCAAT1), the proximal 
C/EBP binding site at -72 to -68 (referred to as CCAAT2) (Figure 2-6A). To address 
whether these two potential CCAAT-boxes are important to mediate the G-CSF/G-
CSFR response of the human mad1 promoter, they were mutated individually or in 
combination. The relevance of the two elements was addressed in combination with 
either the mad1 promoter (-184 to +247-luc) or with the unrelated mintk (-184 to -59-
mintk-luc). Mutating the distal CCAAT-box showed little effect on -184 to +247-luc, 
while disruption of the proximal CCAAT-box alone reduced the activity of the mad1 
promoter by half. Mutation of both CCAAT-boxes showed little additional reduction in 
response to G-CSF/G-CSFR (Figure 2-6B). To determine whether CCAAT-box 
mutants were also relevant in combination with an unrelated core promoter, the -184 
to -59 mad1 promoter fragment and the CCAAT-box point mutated fragments were 
cloned upstream of the mintk promoter. Similar to the findings with the mad1 
promoter, mutating both CCAAT-boxes inhibited most the G-CSF/G-CSFR effect, 
whereas mutation of individual CCAAT-box as resulted in a partial inhibition (Figure 
2-6C). These findings lead to the suggestion that CCAAT-boxes are involved in 
mediating the G-CSF/G-CSFR response of the mad1 promoter. 
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Figure 2-6. CCAAT-boxes mediate part of the G-CSF/G-CSFR response of the mad1 promoter. 
A) Two potential CCAAT-boxes are indicated within the -184 to -59 mad1 promoter fragment. B) 
Relative activation of the indicated mad1 promoter constructs in response to G-CSF/G-CSFR. wt 
refers to the mad1 reporter fragment from -184 to +247 and pGL2 is the promoter-less luciferase 
vector that was used as negative control. ΔC/EBP1 and ΔC/EBP2 indicate that the potential CCAAT-
box1 and 2, respectively, were mutated. ΔC/EBP1+2 indicates both CCAAT-boxes were mutated. C) 
As in panel B but the G-CSF/G-CSFR response element of the mad1 promoter, i.e. the -184 to –59 
region, was cloned in front of the mintk promoter.  
To verify these findings, the stimulation of the -184 to +247 mad1 promoter fragment 
by G-CSF/G-CSFR was compared to the stimulation of the promoter fragment in 
which both CCAAT-boxes were mutated and with a mad1 promoter fragment without 
the responsive region (-58 to +247 mad1 promoter fragment). The luciferase vector 
without a promoter served as negative control. Mutation of both potential CCAAT-
boxes resulted in a remarked reduction in responsiveness to G-CSF/G-CSFR (Figure 
2-7). Furthermore the promoter fragment without responsive region (i.e. -58 to +247) 
showed little response to G-CSF/G-CSFR while the control reporter was 
unresponsive. However, of note is that that the promoter with both CCAAT boxes 
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mutated as well as the promoter fragment without responsive region (i.e. -58 to +247) 
are still partially responsive to G-CSF/G-CSFR (Figure 2-7). This suggests that 
although the two potential CCAAT-boxes are important to mediate the response, 
additional sites in both the responsive region as well as in the core promoter 
fragment are also mediating some response to G-CSF/G-CSFR. It is also worth 
pointing out that the co-expression of the G-CSFR in the absence of stimulation by 
G-CSF was sufficient to stimulate the activity of mad1 promoter-luciferase reporter 
gene constructs. This is most likely due to dimerization and ligand-independent 
autoactivation of the overexpressed receptor.   
 
Figure 2-7. G-CSF/G-CSFR-dependent regulation of mad1 promoter constructs. 
-184 to +247 represents the wild type mad1 promoter fragment; ΔC/EBP1+2 refers to the mad1 
promoter fragment with both potential CCAAT-boxes mutated; -58 to +247 represents the promoter 
without the G-CSF/G-CSFR-response element; and pGL2 is the promoter-less luciferase vector that 
was used as negative control. 
2.2.4 Mutation of GC-boxes reduces the mad1 promoter activity but shows 
little effect on G-CSF/G-CSFR induction 
In addition to the two potential CCAAT-boxes, two GC-boxes are located within the -
184 - +247 mad1 promoter fragment. These sites are of interest since in TATA-less 
promoters GC-boxes have been suggested to function in core promoter activity. In 
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addition Sp proteins, which can bind to GC-boxes are also targets of signal 
transduction pathways. The distal GC-box (from -88 to -96) is located between the 
two CCAAT-boxes and the proximal GC-box (from -18 to -26) lies in the -58 - +247 
mad1 promoter fragment (Figure 2-8A). To examine the roles of these two GC-boxes 
on the regulation of the expression of human mad1 gene, the potential GC-boxes 
were mutated individually or in combination. As shown in Figure 2-8B, mutation of the 
distal GC-box had little effect while mutation of the proximal box reduced the G-
CSF/G-CSFR responsiveness to half. The loss of both boxes showed an additive 
effect. Interestingly, if the inducibility of G-CSF/G-CSFR was compared, there was 
almost no change of the promoter activity by ΔSP1 mutant (Figure 2-8B). However, 
when the G-CSF-response element was cloned into the mintk promoter, a moderate 
reduction was observed when the distal GC-box was mutated (Figure 2-8B). These 
data suggest that GC-boxes are involved in the mad1 promoter regulation. 
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Figure 2-8. Relevance of the GC-boxes. 
A) The two potential GC-boxes are indicated. B) Relative promoter activity of the wt promoter and the 
promoters with mutated GC-boxes. The values represent the fold induction as compared to each 
control. C) Relative induction activation of indicated reporters by G-CSF/G-CSFR. wt refers to the 
mad1 promoter fragment from -184 to +247, ΔSP1 and/or ΔSP2 indicate that the GC1- and/or GC2-
boxes were mutated, respectively. pGL2 refers to the promoter-less reporter that was used as 
negative control. The results represent the mean ± S.E. of three independent transfection experiments 
with triplicate samples, while ∗ represents one typical experiment with triplicate samples. 
2.2.5 Cooperativity between CCAAT- and GC-boxes  
In a next set of experiments the interaction of the putative CCAAT and GC boxes was 
analyzed. The corresponding sites were mutated in the context of the -184 to +247 
mad1 promoter fragment (Figure 2-9A). The proximal GC-box was not included in 
this analysis because the -58 to +247 mad1 promoter fragment demonstrated little 
promoter activity and was poorly stimulated by G-CSF/G-CSFR, indicating that the 
proximal GC-box is of little importance. Mutation of the distal GC box synergized with 
the loss of the two CCAAT boxes, resulting in a substantial reduction of G-CSF/G-
CSFR-mediated induction of luciferase activity (Figure 2-9B). Similarly the stimulation 
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of -184 to -59 mintk-luc by G-CSF/G-CSFR was largely abrogated by mutating the 
two CCAAT- and the GC-boxes (Figure 2-9C), suggesting that these three elements 
are critical to mediate the response to G-CSF/G-CSFR within the homology region of 
the mad1 promoter. Finally, the -184 to +247/ΔC/EBP1+2/ΔSP1 mad1 promoter was 
compared to the -58 to +247 mad1 promoter. The activation by G-CSF/G-CSFR was 
comparable for these two promoters further supporting the critical role of the CCAAT- 
and GC-boxes as the elements through which the receptor-dependent signaling is 
mediated (Figure 2-9D). Thus, these findings suggest that three conserved sites, two 
CCAAT-boxes and the distal GC-box, cooperate and mediate a substantial part of 
the G-CSF/GCSFR-response on the mad1 promoter. 
 
Figure 2-9. Cooperation between the CCAAT- and GC-boxes. 
A) CCAAT- and GC-boxes are indicated within the G-CSF/G-CSFR-responsive mad1 promoter 
fragment. The sites that were mutated are indicated in red. B and C) Standard transient transfections 
in RK13 cells were performed using the indicated reporter gene constructs. The results represent the 
mean ± S.E. of three independent transfection experiments with triplicate samples. D) Comparison of 
the relative activity of the indicated mad1 promoter fragments and the compound one. One 
representative experiment with triplicate samples is shown. 
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2.3 Transcription factors involved in the regulation of the mad1 gene  
The data thus far define elements, including potential CCAAT- and GC-boxes that 
mediate the G-CSF/G-CSFR response of the mad1 promoter. To identify 
transcription factors that control the expression of the mad1 gene in response to G-
CSF, the effects of different C/EBP and Sp proteins were analyzed by using transient 
reporter gene assay. 
2.3.1 C/EBP transcription factors activate mad1 reporter genes 
To address the roles of CCAAT-box binding factors, the effects of different C/EBP 
proteins were assessed on the human mad1 promoter by using transient reporter 
gene assays. Expression plasmids encoding C/EBPα, C/EBPβ and C/EBPε were co-
transfected with -184 - +247 mad1 promoter reporter. Of the three tested C/EBP 
proteins, C/EBPβ and C/EBPα activated -184 - +247 mad1 promoter fragment 
efficiently (about 25 and 14 fold, respectively), whereas C/EBPε was a poor 
stimulator (Figure 2-10A). To address whether the activations were dependent on the 
identified CCAAT-boxes, C/EBP proteins were co-expressed with -184 - +247 mad1 
promoter reporter and mutants thereof. The activation of the -184 - +247 mad1 
promoter reporter with mutated CCAAT-boxes was reduced in response to all three 
isoforms, albeit to various extent (Figure 2-10B, C, and D). Especially for C/EBPβ, 
mutation of either CCAAT-box resulted in a reduction of mad1 promoter activity to 
half, while mutation of both CCAAT-boxes caused almost 80% reduction (Figure 2-
10C). Similarly in the context of the mintk promoter both CCAAT-boxes were relevant 
to mediate stimulation by C/EBPβ (Figure 2-10E). Interestingly mutation of GC-box 
alone was sufficient to significantly reduce C/EBPβ-mediated activation (Figure 2-
10E). The loss of all three sites that were shown to mediate most of the G-CSF/G-
CSFR response resulted in an almost complete loss of responsiveness to C/EBPβ 
(Figure 2-10E), suggesting that the distal GC-box, in addition to the two CCAAT-
boxes, is required for maximal response to C/EBPβ. These data infer that C/EBP 
proteins play an important role in the activation of the mad1 gene. 
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Figure 2-10. C/EBP proteins activate the mad1 promoter.  
A) Three different C/EBP isoforms were co-transfected with mad1 reporter genes into RK13 cells 
and luciferase activity was measured afterwards. B, C and D) C/EBPα, C/EBPβ and C/EBPε , 
respectively,  were co-transfected with the indicated reporter gene constructs. E) The mintk 
promoter containg the G-CSF/G-CSFR response element from -184 to -59 or mutated versions of 
the reporter element were co-transfected with an expression plasmid for C/EBPβ. The results 
represent the mean ± S.E. of at least two independent transfection experiments with triplicate 
samples. Reporter gene assays were performed as described previously.   
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2.3.2 Involvement of Sp1 protein in the repression of mad1 expression 
To address whether Sp1 proteins affect the expression of the human mad1 promoter, 
plasmids expressing HA-tagged Sp1 protein and the -184 - +247 mad1 promoter 
were co-transfected into RK13 cells in the absence or presence of the G-CSF/G-
CSFR. In the absence of G-CSF/G-CSFR neither of three Sp1 proteins (Figure 2-11A) 
showed any activity towards the mad1 promoter (Figure 2-11B, C and D). However in 
the presence of G-CSF/G-CSFR, the full-length Sp1 protein activated the reporter in 
a dose-dependent manner. Similarly, Sp1-C, which lacks the classical transactivation 
domain, also stimulated transcription (Figure 2-11B and C). Those effects were quite 
modest. In contrast, there was no effect on the mad1 promoter by co-expressing Sp-
N, which lacks the DNA binding domain (DBD domain) (Figure 2-11D). These 
findings suggest that Sp1, as indicated from the analysis of the GC-box mutations, 
participates in mediating the G-CSF/G-CSFR signals. For this the DBD and the C-
terminal region of Sp1 appear to be important.  
 
Figure 2-11. Involvement of Sp1 proteins in the regulation of the mad1 promoter. 
A) A schematic diagram of the HA-tagged Sp1 proteins. DBD: DNA binding domain. B, C, and D) The 
-184 - +247 mad1 reporter gene was co-transfected with experiments for full-length Sp1, Sp1-C and 
Sp1-N proteins as indicated. The reporter assay was performed as described in Figure 2-3. The dose 
of Sp1 proteins was 0 µg, 0.5 µg, 1 µg, 2 µg, and 4 µg. The results represent the mean ± S.E. of at 
least three independent transfection experiments with triplicate samples. 
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2.3.3 Involvement of STAT3 protein in the activation of the mad1 promoter 
STAT proteins are important mediators of the G-CSF/G-CSFR signal transduction. 
One non-typical STAT-binding site is located within the 400bp high homology region 
(Figure 2-2). However this site does not localize to the G-CSF/G-CSFR-responsive -
184 - +247 region of the mad1 promoter. Nevertheless whether STAT proteins have 
possible roles in the regulation of mad1 promoter was tested. Therefore, plasmids 
expressing STAT1, STAT3 and STAT5 were co-transfected with -184 - +247 mad1 
reporter into RK13 cells in the absence or presence of the G-CSF/G-CSFR. As 
shown in Figure 2-12A, while STAT3 demonstrated a strong activation of the reporter, 
neither STAT1 nor two different STAT5 isoforms showed any effect, suggesting that 
STAT3 is functionally relevant for the G-CSF/G-CSFR-mediated activation of the 
mad1 reporter gene. Furthermore, if STAT3 with a tyrosine 705 to phenylalanine 
mutation was used, STAT3-Y705F can not be tyrosine phosphorylated by JAK 
kinases associated with the G-CSFR and therefore cannot form homodimers and 
translocated efficiently to the nucleus, the activation of the mad1 promoter in 
response to G-CSF/G-CSFR was repressed (Figure 2-12B). Similarly, dominant 
negative STAT3 (STAT3dn) lacking the DNA binding domain, also repressed. These 
findings suggest that STAT3 is important to mediate the G-CSF/G-CSFR-response. 
Whether the requirement of the DNA binding domain of STAT3 indicates that STAT3 
needs to contact DNA or whether the DNA binding domain has additional functions 
has not been resolved. STAT3dn and STAT3-Y705F inhibit G-CSF/G-CSFR 
signaling most likely by interfering with endogenous STAT3 of RK13 cells. Indeed 
STAT3 was phosphorylated by G-CSF/G-CSFR signaling in these cells (Figure 2-
12C). Together these studies define STAT3 as a potentially important mediator of G-
CSF/G-CSFR signaling to the mad1 promoter. 
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Figure 2-12. Involvement of STAT3 in the activation of mad1 promoter. 
A) Transient reporter gene assays in RK13 cells were performed with the indicated reporter gene and 
STAT expression plasmids. One representative experiment performed in triplicates is displayed. B) 
Dominant negative STAT3 proteins, i.e. STAT3-Y705F and STAT3dn, were expressed in the presence 
of the indicated reporter gene constructs. The results represent the mean ± S.E. of three independent 
transfection experiments with triplicate samples. C) The human G-CSFR was expressed in RK13 cells. 
Before harvesting, the cells were stimulated with G-CSF (10 ng/ml) for 1 h and endogenous STAT3 
was analyzed by western blotting. The phosphorylated STAT3 was detected by antibody specific for 
STAT3-Tyr705P and the total STAT3 was stained for control. 
2.4 Transcription factors binding to the endogenous mad1 promoter in 
response to G-CSF 
The findings obtained so far define CCAAT- and GC-boxes and factors that can bind 
to these elements as important to regulate the mad1 promoter in response to G-
CSF/G-CSFR in transient reporter gene assays. To investigate whether the 
endogenous mad1 promoter is occupied by the relevant factors either before or after 
stimulation by G-CSF, the chromatin immunoprecipitation (ChIP) assay was 
employed. Besides the transcription factors of interest, including members of the 
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C/EBP family and Sp proteins, some basal components of the transcription 
machinery, such as polymerase II and acetylation of the core histone H3 and H4, 
were investigated.  
2.4.1 C/EBP transcription factors are recruited to the human mad1 promoter 
To determine whether endogenous C/EBP transcription factors bind in vivo to the 
mad1 promoter in response to G-CSF, ChIP experiments were performed. U937 cells 
were stimulated with G-CSF for various times, crosslinked and subsequently sheared 
by sonication to obtain small DNA fragments in the range of 500~1000bp. Specific 
protein-DNA complexes were immunoprecipitated with antibodies specific for the 
proteins of interest. The associated DNA was then analyzed by PCR for the presence 
of mad1 promoter fragments. PCR amplification was conducted using primer pairs 
specific for the regulatory region (F/R3) and a control region (F/Rc) of the mad1 
promoter (Figure 2-13A). The latter primer set was included as negative control to 
evaluate whether the signals observed were specific for the regulatory region of the 
mad1 promoter. The input DNA was amplified as positive control and used to assess 
the sensitivity range of the assay in parallel PCRs using increasing amounts of a 
control template (Figure 2-13B). The ChIP analyses revealed that C/EBPα and 
C/EBPβ were constitutively bound to the mad1 promoter irrespective whether the 
cells were treated with G-CSF or not (Figure 2-13B). However upon G-CSF treatment, 
a shift from preferentially C/EBPα to C/EBPβ was detected at the mad1 promoter. In 
contrast, for C/EBPε no binding above background (anti-Cyto C) could be measured. 
Concomitant with the stimulation by G-CSF and the increase in C/EBPβ binding, an 
increased association of Polymerase II with the mad1 promoter was observed that 
correlated with the increased expression of the mad1 gene in response to G-CSF 
(Figure 2-13B). However, no difference in the overall acetylation of histone H3 and 
H4 and in the methylation of histone H3K4 was observed (Figure 2-13B), despite the 
induction of mad1 expression in response to G-CSF/G-CSFR. This supports our 
previous notion that the chromatin over the homology region, which contains the core 
promoter and the G-CSF/G-CSFR-responsive region, possesses open chromatin and 
may thus be in a permissive state. Taken together, these findings indicate that C/EBP 
proteins can interact with the mad1 promoter in U937 cells independent of G-CSF 
stimulation. 
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Figure 2-13. Differential binding of C/EBP proteins and polymerase II to the mad1 promoter in 
response to G-CSF. 
A) The primer pairs are indicated that are specific for the regulatory region (F/R3) and a control region 
(F/Rc) of the mad1 promoter used for PCR amplification in the ChIP. The PCR product of the F/R3 
primer pair is 224bp and amplifies from -182 to +42, while the PCR product of the F/Rc primer pair is 
257bp and amplifies from +1176 to +1432. B) The presence of C/EBPα, C/EBPβ, C/EBPε, Polymerase 
II, acetylated histone H3 (AcH3) and histone H4 (AcH4), and histone H3 dimethylated at lysine 4 (H3-
K4-diM) at the endogenous mad1 promoter was measured by CHIP assay in response to G-CSF 
treatment. Antibodies specific for Cytochrome C (Cyto-C) were used as negative control. For 
comparison serial dilutions of input chromatin DNA was analyzed. C: no G-CSF treatment; .5, 1, and 2 
indicates the time in hours of G-CSF (10 ng/ml) treatment. 
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2.4.2 Sp transcription factors interact with the endogenous human mad1 
promoter 
To investigate whether Sp proteins and which isoform interact with the GC-boxes of 
the mad1 promoter, electrophoretic gel mobility shift assays (EMSA) were performed. 
Nuclear extracts of U937 cells, treated with G-CSF for various times, were incubated 
with [32P]-labelled SP probes in the presence or absence of antibodies specific for Sp 
proteins. The protein/DNA complexes were separated by non-denaturing 
polyacrylamide gels. As shown in Figure 2-14A, four different protein/DNA complexes, 
i.e. C1 trough C4, were detected with a double-stranded oligonucleotide 
encompassing the distal GC-box. The sequence of SP probe 1 is 5’-
AAGTGTAGGGGCGGGGCATTCT-3’. The C2 complex could be supershifted by 
antibodies against Sp1, whereas C1, C3, and C4 could all be supershifted by an 
antibody against Sp3, suggesting that this GC-box interacted with several different 
Sp protein-containing complexes. None of these protein/DNA complexes could be 
supershifted by antibodies specific for cytochrome C that were used as negative 
control (see also comments in the figure). Interestingly, no binding to the proximal 
GC-box containing oligonucleotide could be detected, although the core sequence of 
both boxes is identical (Figure 2-14A). These data indicate that the ubiquitous 
expressed transcriptional regulators Sp1 and Sp3 can interact at least with the distal 
GC-box of the mad1 promoter.  
 
The in vitro binding of Sp1 and Sp3 measured in EMSA was verified in ChIP 
experiments. As shown in Figure 2-14B, binding of Sp1 and Sp3 to the mad1 
promoter, but not to a control region, could be detected. Slight reproducible variations 
in the extension of binding could be observed in response to G-CSF treatment. Of 
note is, that the binding of both proteins was reduced when G-CSF-induced mad1 
expression was maximal (Figures 2-1A and 2-14B).  
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Figure 2-14. Binding of Sp proteins to the mad1 promoter. 
A) 8 µg nuclear extract of U937 cells treated with or without G-CSF was first incubated with 32P-
labeled double stranded mad1 promoter oligonucleotides (SP probe 1: 5’-
AAGTGTAGGGGCGGGGCATTCT-3’, from –97 to -82; SP probe 2: 5’-
AAGGGGCTGGGGGCGGGGAGATG-3', from – 35 to - 13, respectively). Then the mixture was 
incubated with 2 µg antibodies specific for Sp1, Sp3 and cytochrome C as indicated. The protein/DNA 
complexes were separated on a 4.5% non-denaturing polyacrylamide gel at 20 V/cm for 4 h at 4°C. 
The gels were fixed for 1 h, dried, and autoradiographed. B) Association of Sp1 and Sp3 proteins with 
the endogenous mad1 promoter were measured in response to G-CSF treatment by CHIP. 
Cytochrome C (Cyto-C) served as negative control. For comparision serial dilutions of input, chromatin 
DNA was analysed. C: no G-CSF treatment, .5, 1, 2: the time in hours of G-CSF (10 ng/ml) treatment. 
The primer pairs used are described in Figure 2-13. 
2.5 G-CSF/GCSFR signal transduction pathway relevant for mad1 expression 
Several distinct pathways have been described that emanate from the G-CSF/G-
CSFR complex. To address in more detail, which signal transduction pathways are 
important to regulate the mad1 promoter, receptor mutants and components of G-
CSF/G-CSFR-regulated signal transduction pathways were analyzed.  
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2.5.1 Structure-function analysis of the G-CSFR: tyrosine residues relevant for 
the activity of the mad1 promoter 
The G-CSF Receptor has been extensively studied and four tyrosine residues (Y704, 
Y729, Y744, and Y764) have been identified as important amino acids to connect the 
G-CSF/G-CSFR complex to intracellular signal transduction pathways. In addition 
three conserved boxes have been linked to receptor function (Figure 2-15A). To 
clarify the role of these elements for signaling to the mad1 promoter, plasmids 
encoding receptor deletion mutants were co-transfected into RK13 cells together with 
the -184 - +247 mad1 promoter construct (All deletion mutants have been described 
in Figure 2-3). Loss of the distal region of the cytoplasmic portion of the G-CSFR, 
including the four tyrosine residues, completely abolished stimulation of the -184 - 
+247 mad1 promoter construct (Figure 2-15B), suggesting that the tyrosine residues 
might play an important role in mediating the signaling to the mad1 promoter. To 
address the role of individual tyrosine residues in the control of mad1 expression, 
receptor mutants in which either individual tyrosine residue were mutated to 
phenylalanine or in which only a single tyrosine residue was maintained were tested 
to evaluate their ability to activate the mad1 promoter. When either only Y704 or only 
Y744 was present, stimulation was more pronounced than with the wild type G-CSFR 
(Figure 2-15C). A receptor mutant with only Y764 showed comparable activity to wild 
type G-CSFR whereas in contrast when only Y729 was present substantially reduced 
mad1 promoter stimulation was observed (Figure 2-15C). The importance of 
individual tyrosine residues was further substantiated with G-CSFR mutants in which 
individual tyrosines were mutated. While loss of Y704 was sufficient to significantly 
reduce activation of the mad1 promoter construct, in the absence of Y729 receptor 
signaling was increased (Figure 2-15C). Loss of either Y744 or Y764 showed little 
consequence. Thus it appears that Y729, which recruits the suppressor of cytokine 
signaling (SOCS) 3, is mainly involved in signal repression. In contrast the other 
three tyrosines mediate activation, with Y704 being the most important residue. Y704, 
as well as Y744, has been implicated in recruiting STAT3 to the receptor. 
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Figure 2-15. Identification of the tyrosine residues of the G-CSFR that mediate the activation of 
the mad1 promoter. 
A) The schematic diagram of the structure of the G-CSFR is shown with the 3 conserved boxes and 
the four tyrosine (Y) residues that are important for signal transduction through the indicated pathways. 
B and C) Different deletion and point-mutated G-CSGR constructs were co-transfected with the mad1 
promoter into RK13 cells. Reporter assays were performed as described in Figure 2-3. The results 
represent the mean ± S.E. of at least two independent transfection experiments with triplicate samples.  
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2.5.2 Involvement of the MAPK signal transduction pathways for mad1 
promoter activation 
The analyses of G-CSFR mutants showed that Y764 is sufficient to mediate part of 
the activation of the mad1 promoter. Since this tyrosine has been suggested to 
engage with the RAS/RAF/mitogen-activated protein kinase (MAPK) pathway, its role 
in regulating mad1 gene expression was addressed. PD98059 and SB202190, which 
inhibit MEK/ERK and p38, respectively, were employed to block specific components 
of the MAPK pathway and the effect of these inhibitors on G-CSF-stimulated mad1 
gene expression was determined. mad1 mRNA expression was assessed by using 
quantitative PCR methods. Inhibition of MEK by PD98059 resulted in a substantial 
reduction of the activation of mad1 gene expression by G-CSF (Figure 2-16A). 
Similarly the p38 inhibitor SB202190 also repressed the G-CSF-induced activation of 
mad1 expression (Figure 2-16B). However, while PD98059 inhibited the TPA-
induced mad1 gene expression, SB202190 had no effect (Figure 2-16A and B). In 
addition, it was verified whether G-CSF was capable to induce ERK activation in 
U937 cells. Indeed in response to G-CSF ERK phosphorylation was induced, which 
was apparent within 15 min of treatment and remained high for at least 2 hours 
(Figure 2-16C). This data indicates that the MAPK pathway, one of the prominent 
signal transduction pathways that are activated by G-CSF/G-CSFR, is relevant for 
signaling to the mad1 promoter. 
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Figure 2-16. The MAPK signal transduction pathway is involved in the activation of mad1 gene 
expression. 
A and B) Effects on the induction of mad1 gene by inhibiting MEK/ERK and p38 with PD98059 and 
SB202190, respectively. After pre-treatment with PD98059 (100 µM) and SB202190 (10 µM) for 40 
min, the U937 cells were incubated with or without G-CSF (10 ng/ml) or TPA (1.6 x 10-8 M) for an 
additional 1 h. Then the cells were harvested and total RNA was isolated. The amount of mRNA was 
analyzed by using quantitative PCR methods. C) G-CSF induces the phosphorylation of ERK proteins. 
After 3h serum starvation, U937 cells were stimulated by G-CSF (10 ng/ml) for the times indicated. 
Whole cell extracts were analyzed by immunoblotting with antibodies against phosphorylated ERK1/2, 
and the membrane was reprobed with antibody against ERK1/2. 
2.5.3 STAT3 is activated in response to G-CSF 
To verify that in U937 cells STAT3 is activated by G-CSF, a heterologous system to 
address induction of STAT3 phosphorylation in response to G-CSF/G-CSFR was first 
established. In HEK293T cells that express exogenous G-CSFR, STAT3 
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phosphorylation was stimulated in response to G-CSF (Figure 2-17A). Even in the 
absence of the G-CSF, with only co-transfected G-CSFR, a small amount of 
activated STAT3 was detectable, probably due to autoactivation of the 
overexpressed G-CSFR, which is consistent with the previous results from the 
reporter assays. To examine the endogenous phosphorylation of STAT3, U937 cells 
were stimulated by G-CSF for different length of time comparable to the observations 
in HEK293T cells, the treatment with G-CSF led to phosphorylation of STAT3 within 
15 min and STAT3-P was detectable over the entire time course (Figure 2-17B). 
These findings support the conclusion that STAT3 is involved in the regulation of the 
expression of the mad1 gene.  
 
Figure 2-17. STAT3 is activated in response to G-CSF. 
A) G-CSF induces the phosphorylation of exogenous STAT3 protein. HEK293T cells were co-
transfected with G-CSFR and STAT3-HA plasmids for 24 to 36 h. After depriving of serum for 3 h, the 
cells were treated with G-CSF for the times indicated and then harvested. IP: The cell extracts were 
immunoprecipitated with antibody specific for the HA-tag. The immunoprecipitates were resolved by 
10% SDS-PAGE and transferred to nitrocellulose membranes and the membranes were probed using 
the antibodies indicated. The lysates were analyzed in the same way. B) G-CSF induces the 
phosphorylation of endogenous STAT3 protein. After 3h serum starvation, U937 cells were stimulated 
by G-CSF (10 ng/ml) for the times indicated and harvested. The detection was performed as described 
in A. 
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2.5.4 G-CSF/G-CSFR-activated STAT3 can stimulate gene transcription 
through interaction with C/EBPβ . 
The findings described thus far identify an important role of STAT3 in the regulation 
of the mad1 promoter by G-CSF/G-CSFR. In addition the CCAAT-boxes and C/EBP 
proteins that bind to these elements convert at least some of the G-CSF/G-CSFR 
signal into promoter activity. Importantly the mad1 promoter does not contain any 
consensus STAT binding sites. This indicates that STAT3 might be recruited to the 
mad1 promoter indirectly. One possibility is that STAT3 interacts with and is 
recruiting C/EBP proteins. Therefore the ability of C/EBPβ to interact with STAT3 was 
tested. Extracts from HEK293T cells that were co-transfected with plasmids 
expressing HA-STAT3 and C/EBPβ were used in co-immunoprecipitation 
experiments. It was observed that STAT3 interacted with C/EBPβ in response to G-
CSF/G-CSFR signaling (Figure 2-18A). Together these findings suggest that STAT3-
dependent signaling can be mediated by C/EBPβ. To evaluate this conclusion further, 
a minimal chicken myelomonocytic growth factor promoter reporter gene construct 
was used. This promoter is driven by two CCAAT-boxes and has been described to 
be exclusively C/EBPβ-responsive (Sterneck et al., 1992). Indeed this reporter but 
not the promoter with mutated CCAAT-boxes was efficiently stimulated by G-CSF/G-
CSFR (Figure 2-18B). The activation was dependent on functional C/EBPβ, since co-
expression of a dominant negative version of this protein blocked the response to G-
CSF/G-CSFR. Importantly STAT3-Y705F and STAT3dn also inhibited G-CSF/G-
CSFR-dependent activation. This data provided further evidence for the hypothesis 
that STAT3 can be recruited through C/EBPβ to target genes resulting in their 
activation.  
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Figure 2-18. The roles of STAT3 and C/EBPβ  
A) Interaction between CEBPβ and STAT3. HEK293T cells were co-transfected with G-CSFR, STAT3-
HA and CEBPβ plasmids. After depriving of serum for 3 h, the cells were treated with the G-CSF (10 
ng/ml) for 1 h. The cell extracts were immunoprecipitated with antibodies specific for C/EBPβ or the 
HA-tag. The immunoprecipitates were resolved by 10% SDS-PAGE and transferred to nitrocellulose 
membranes and the membranes were probed using the antibodies indicated. The lysates were 
analyzed in the same way and used for protein expression control. β-actin was stained as loading 
control. B) Activation of C/EBP-driven promoters in response to G-CSF/G-CSFR. cMGF: chicken 
myelomonocytic growth factor promoter.  
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3 Discussion 
It is well established that the Myc/Max/Mad network tightly controls cell behavior in 
order to keep the balance between normal cell growth and differentiation (Luscher 
and Larsson, 1999; Grandori et al., 2000). Mad1 is a member of this network and 
functions as an antagonist of Myc. Most studies on Mad1 have focused on its role as 
a repressive transcription factor and the biological activities associated with this 
repressor function. The loss of Mad1 protein results in a delayed granulocyte 
differentiation, while overexpression of Mad1 leads to the inhibition of cell growth and 
proliferation. In addition, Mad1 is typically expressed in a variety of cells undergoing 
differentiation, especially in differentiating hematopoietic cells, and also in non-
cycling terminally differentiated cells (Ayer and Eisenman, 1993; Larsson et al., 1997; 
Foley et al., 1998; Grandori et al., 2000). These findings suggest that Mad1 is an 
important regulator of differentiation processes, in particular in myeloid cells. Thus, 
understanding the regulation of Mad1 expression will provide further insight into 
Mad1-dependent regulation of cell behavior, including granulopoiesis. In this study, 
the induction of the mad1 gene in a cell differentiation system was first examined. 
Then, the mad1 promoter was identified and promoter elements were characterized. 
Furthermore, the G-CSF-induced signal transduction pathways relevant for the 
activation of mad1 expression were defined. Finally, potential mechanisms involved 
in the regulation of mad1 at the transcriptional level are discussed.  
3.1 Selection and establishment of a human mad1 expression system 
To study the expression of the mad1 gene, we were interested to use a cell-based 
differentiation system that would allow easy manipulation in order to study the 
regulatory circuitries that control mad1 transcription. Since in the mouse Mad1 
deregulation affects primarily granulocytic differentiation, the cell system should allow 
to address late myeloid differentiation. Among the many different approaches that 
have been used to study differentiation of myeloid cells, different cell systems have 
been widely used, one being the murine myeloid 32D cell, others involve the human 
promyelocytic cell lines U937 and HL60. In the former cell line in vivo differentiation is 
closely mimicked, because 32D cells are able to differentiate from blast-like cells into 
mature neutrophils (Ward, et al., 1999b). The advantage of this system is that many 
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differentiation associated markers can be monitored. However, the disadvantage of 
this system is that the 32D cells do not express endogenous G-CSFR. However with 
the role of Mad1 in granulocytic differentiation as seen in the mouse and our earlier 
findings that G-CSF can regulate mad1 expression (Sommer et al. 1998), one option 
is to introduce the G-SCFR into 32D cells (32D/WT). This has been done and the 
expression of murine mad1 has been studied. But murine mad1 expression was not 
detectable in 32D/WT cells until day five of G-CSF treatment and the induction was 
weak (Dr. Ivo Touw, personal communication). Thus this induction time is rather long, 
which makes it difficult to establish a direct link between the inducer and the target 
gene, which is a major disadvantage for the analysis of signal-dependent gene 
regulatory events.  
The human hematopoietic cells lines U937 and HL60 are widely used to investigate 
the molecular mechanisms of differentiation (Larsson et al., 1994; A. Sommer, 
Dissertation, 1997; Xiao et al., 2002). These cells can be differentiated upon 
stimulation by various physiological and non-physiological agents. In this study, the 
U937 differentiation system was chosen since it has been shown previously that 
mad1 can be regulated in these cells (Larsson et al., 1994; A. Sommer, Dissertation, 
1997). In addition, U937 cells express the G-CSFR (Fukunaga et al., 1990), which is 
the prerequisite to study the regulation of mad1 expression in response to G-CSF.  
On the basis of the data presented in this study, the induction of mad1 expression by 
G-CSF in U937 cells is rapid and detectable as early as 0.5 h after stimulation. 
Maximal expression is observed between one and two hours of stimulation and then 
declines (Figure 2-1A). Similarly, TPA could also induce the rapid expression of 
mad1 mRNA (Figure 2-1A). This suggested that the induction of mad1 mRNA by both 
G-CSF and TPA is a direct effect. However, G-CSF and TPA may stimulate different 
signal transduction pathways to induce the expression of mad1 in U937 cells. Similar 
observations were made in HL60 cells in response to both G-CSF and TPA (Figure 
2-1C). Importantly, treatment with cycloheximide did not block G-CSF-induced mad1 
mRNA expression, suggesting that the induction of mad1 mRNA is independent of de 
novo protein synthesis (Figure 2-1B). Furthermore, a similar induction of human 
mad1 mRNA upon G-CSF stimulation has also been observed in primary myeloid 
progenitors (Figure 2-1D), further supporting a role of Mad1 in granulopoiesis. Taken 
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together, the findings presented in this study suggest that the mad1 gene is induced 
during the differentiation process of hematopoietic cells. These findings are 
consistent with previous work (A. Sommer, Dissertation, 1997), which demonstrated 
the induction of mad1 expression in U937 cells. In addition, it supports the view that 
the U937 differentiation system can be used to investigate the regulatory 
mechanisms of mad1 expression. 
3.2 Regulation of the human mad1 promoter at the transcriptional level 
3.2.1 Identification and characterization of the mad1 promoter 
Our previous work has delineated that the human mad1 genes spans over 23 kbp of 
genomic DNA and possesses 6 exons. Comparing the genomic sequences 5’ of the 
coding regions between human, rat and mouse, a 400bp region was identified with 
high homology (Figure 2-2). Using both rapid amplification of cDNA ends (RACE) 
techniques and primer extension assays to investigate the start of transcription site, 
the putative core promoter region of mad1 was identified. The most prominent start of 
transcription site was identified within the homology region. With this information a 
putative human mad1 promoter fragment, from -1282 to +247, which includes the 
complete homology region, was cloned and analyzed (K. Eckert, dissertation, 2004). 
Evaluation of this sequence revealed that, like the promoters of other mad genes 
(Benson et al., 1999; Fox and Wright, 2003; Kime and Wright, 2003), no canonical 
TATA boxes are present in the vicinity of the human mad1 core promoter. However, 
this sequence possesses multiple CCAAT- and GC-boxes (Figure 2-2). In addition, it 
has several non-typical initiator sequences and 4 MED (multiple start site element 
downstream) sequences, but no DPE (down stream core promoter element). 
Importantly, the 400bp homology region contains potential C/EBP, Sp, c-Myb, PU.1 
binding sites, and a non-typical STAT consensus binding site (Figure 2-2). The 
presence of these elements clustering within the conserved region upstream of the 
mad1 transcriptional start site suggests that this conserved region functions as 
promoter and that its regulation might be controlled by the cooperativity between 
these binding sites and the respective transcription factors.  
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Subsequent promoter analyses confirmed that a genomic fragment of the mad1 locus 
spanning from -1282 to +247 relative to the most 5’ start site of transcription mapped 
has promoter activity and was stimulated by G-CSF. Importantly deletion analysis 
showed that the fragment from -184 to +247 possesses maximal promoter activity 
and was stimulated efficiently by G-CSF (Figure 2-3). The latter construct includes 
part of the homology region, in which most of the core promoter elements seem to be 
localized. Smaller promoter fragments have less basal and G-CSF-inducible activity, 
suggesting, together with the location of the start site of transcription, that this -184 - 
+247 mad1 fragment contains the functional mad1 promoter.  
The induction of mad1 mRNA in U937 cells in response to G-CSF demonstrated a 
roughly 3-fold increase (Figure 2-1), an activation that was similar to the activation of 
the -1282 to +247 mad1 promoter-luciferase construct in RK13 cells (Figure 2-3). 
This latter finding was in contrast to smaller promoter fragments that were activated 
more efficiently by G-CSF. Deletion of the sequence from -1282 to -796 strongly 
increased the G-CSF/GCSFR-mediated activation of the mad1 promoter while 
deletion of the sequence from -184 to -59 almost totally abrogated the activation of 
the promoter (Figure 2-3). These findings suggest that human mad1 promoter is 
controlled by both negative and positive regulatory regions. 
By using RK13 cells a heterologous system, almost no promoter activity was 
observed from different mad1 promoter constructs in the absence of co-expressed G-
CSFR (Figure 2-3). But in the presence of G-CSFR, stimulation with G-CSF resulted 
in a substantial activation of the promoters (Figure 2-3). This led to the notion that the 
human mad1 promoter is responsive to G-CSF-mediated signals and that it might 
contain a G-CSF-responsive regulatory region(s). Consistent with this, deletion of the 
sequence from -184 to -59 totally abrogated the activation of the promoter (Figure 2-
3), suggesting that the fragment from -184 to -59 or portions of it function as G-CSF-
responsive element(s). Similar results were obtained with reporter gene constructs, in 
which the -184 to -59 fragment was subcloned into a reporter with a minimal tk 
promoter, an unrelated core promoter. In this setting the -184 to -59 fragment was 
tested for enhancer activity in response to G-CSF/G-CSFR (Figure 2-4) and it was 
confirmed that this region contained one or several G-CSF-responsive elements. As 
Discussion  62 
 
for the negative regulatory region, additional experiments will be required to 
determine their identity and function. 
3.2.2 Regulation of the activity of the mad1 promoter in response to G-CSF by 
C/EBP proteins through functional C/EBP binding sites  
Several transcription factors, including C/EBP, Sp and Myb proteins, have putative 
binding sites in the G-CSF-responsive region. Of those, two consensus C/EBP 
binding sites are of special interest since factors that bind to these elements are 
important in controlling myeloid differentiation (Nakajima and Ihle, 2001). In this study, 
the effect of these two C/EBP binding sites was investigated in more detail. The 
disruption of the proximal C/EBP binding site resulted in a stronger reduction of 
promoter activity when compared to the distal C/EBP binding site. The loss of both 
sites decreased mad1 promoter activity maximally (Figure 2-6, Figure 2-7). 
Nevertheless, some remaining activity was still observed when a promoter with both 
C/EBP binding sites mutated was compared to a mad1 promoter without responsive 
region (Figure 2-6, Figure 2-7). One explanation might be that the potential Sp and/or 
Myb protein binding sites are implicated in the regulation of the mad1 gene. In 
addition, PU.1, a transcription factor implicated in the regulation of myeloid 
differentiation (Fisher and Scott, 1998), might also be a target of G-CSF-dependent 
signaling. Together, these results suggest that both C/EBP binding sites are 
functionally important and mediate the majority of the G-CSF response. However, it is 
well possible that other factors participate in this response, either independently of 
C/EBP factors or, more likely, in cooperation with these proteins.  
C/EBP proteins are basic region-leucine zipper transcription factors that act as critical 
regulators of numerous cellular responses, including the control of cell proliferation 
and differentiation and immune and inflammatory processes. C/EBP proteins exert 
their functions through binding to CCAAT-boxes. Three members of the C/EBP family 
(C/EBPα, C/EBPβ, and C/EBPε) are expressed in myeloid cells and show a unique 
expression profile during myeloid cell differentiation (Ramji and Foka, 2002; Nerlov, 
2004). Furthermore knock-out studies in mice and deregulated expression in myeloid 
cell lines demonstrated the importance of the correct expression of C/EBP proteins 
for faithful myeloid differentiation (Tenen et al., 1997; Ward et al., 2000). In addition 
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to the unique expression patterns, C/EBPα, C/EBPβ, and C/EBPε proteins are 
translated as several N-terminally truncated isoforms, which can form different 
homodimers and heterodimers through their ZIP domains (Lekstrom-Himes and 
Xanthopoulos, 1998; Ramji and Foka, 2002). Since the transactivation activity is 
located near the N-terminus, these isoforms possess distinct functions, i.e. some 
isoforms display activating, others repressing gene regulatory activities. Together, 
these findings define complex regulatory processes, including decisive expression 
patterns, different isoforms and distinct dimeric complexes, that control C/EBP 
protein function to ensure proper differentiation of myeloid cells.  
To address the role of C/EBP proteins on the human mad1 promoter, expression 
plasmids encoding C/EBPα, C/EBPβ or C/EBPε were co-transfected with mad1 
promoter reporters. The results showed that all three tested C/EBP proteins activate 
the promoter, with C/EBPβ being the most efficient followed by C/EBPα, while 
C/EBPε had little effect (Figure 2-10A). This result does not reflect a quantitative 
analysis since the expression of the three proteins could not be compared directly. 
To address the relative activities of the three proteins, tagged versions should be 
used under conditions of equal expression. If the C/EBP binding sites were mutated, 
C/EBP-dependent stimulation of promoter activity was lost (Figure 2-10B, C and D). 
Similar results were obtained in the context of the mintk promoter, neither C/EBP 
protein activated this promoter-reporter construct (Figure 2-10E). These data support 
the concept that C/EBPα and/or C/EBPβ proteins play an important role in the 
regulation of mad1 expression through specific sites in the proximal promoter region. 
This regulation might be closely associated with the control of cell differentiation and 
inhibition of apoptosis.   
C/EBPα is known to induce granulopoiesis but suppress monocyte differentiation 
(Radomska et al., 1998). C/EBPα-deficient mice fail to undergo myeloid 
differentiation beyond the myeoblast stage and, therefore, lack mature neutrophils 
(Zhang et al., 1997). C/EBPα binds to TFIIB and TBP and recruits the RNA 
polymerase II basal transcriptional apparatus to activate target promoters and 
subsequently to regulate differentiation-specific genes (Nerlov and Ziff, 1995; 
Pedersen et al., 2001; Muller et al., 2004). It is possible that C/EBPα plays a similar 
role in the regulation of the mad1 promoter. Consistent with this idea is our finding 
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that C/EBPα constitutively occupies the proximal mad1 promoter region as 
demonstrated using ChIP (Figure 2-13B), although the binding was reduced upon 
treatment with G-CSF. Moreover, the overall acetylation of histone H3 and H4 and 
the methylation of histone H3K4 at the mad1 promoter (Figure 2-13B) supports our 
previous notion that the chromatin over the homology region, which contains the 
proximal promoter, is in an open configuration (K. Eckert, dissertation, 2004). This 
may provide a prerequisite for the activation of the mad1 gene. 
 
Interestingly, following G-CSF treatment, a shift from preferentially binding of C/EBPα 
to C/EBPβ on the human mad1 promoter was observed (Figure 2-13B). In addition 
an increased association of polymerase II with the mad1 promoter was found, 
presumably the consequence of G-CSF-induced signaling to the mad1 promoter, 
explaining the increased transcription measured (Figure 2-13B). It is conceivable that 
increased levels of C/EBPβ could displace C/EBPα in the context of the mad1 
promoter. Without G-CSF treatment, C/EBPα could occupy the promoter but not 
trigger efficiently gene transcription. Upon G-CSF treatment, activated ERK1/2 might 
alter the conformation of C/EBPα by phosphorylating serine 21 (Ross et al., 2004). 
This might reduce the affinity between the two C/EBPα subunits, leading to the 
subsequent destabilization of C/EBPα homodimers that might affect homo- and 
heterodimerizations between different C/EBP proteins. In response to G-CSF 
signaling, C/EBPα may first form heterodimers with C/EBPβ because of their 
increased affinity (Lekstrom-Himes and Xanthopoulos, 1998). Then, C/EBPα may be 
completely replaced by C/EBPβ. Thus the signaling may affect dimer formation and 
expression levels, the different hetero- and homodimers may compete for the binding 
sites on the mad1 promoter, finally resulting in the substitution of C/EBPα 
homodimers with C/EBPα/β hetero- and/or C/EBPβ homodimers. This model is 
supported by the findings that ERK-dependent phosphorylation changes the 
conformation of C/EBPα and inhibits granulopoiesis (Ross et al., 2004). Furthermore 
ERK signaling converts C/EBPβ from a suppressed into an activated transcription 
factor (Nakajima et al., 1993; Kowenz-Leutz et al., 1994). C/EBPβ is normally 
unphosphorylated and localized in the cytoplasm of multipotential cells (Chinery et al., 
1997). Phosphorylation stimulates nuclear uptake and the transcriptional potential of 
C/EBPβ in granulocyte-committed cells in response to differentiation stimuli (Ford et 
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al., 1996). Binding of G-CSF to its receptor in U937 cells may therefore induce an 
activation cascade in which C/EBPβ becomes phosphorylated, and participates in the 
transcriptional activation of the mad1 gene and perhaps other granulocyte specific 
genes. Together with the finding obtained in response to overexpressed C/EBP 
transcription factors (Figure 2-10), it can be suggested that C/EBPβ, rather than 
C/EBPα, plays the key role in the activation of mad1 expression in response to G-
CSF signaling. However, the mechanisms and the biological significance of the 
individual isoforms of the C/EBP family, in particular the shift from C/EBPβ to 
C/EBPα, will need to be determined in the future. 
 
Several findings suggest that C/EBPε functions as a critical regulator of 
granulopoiesis. First, unlike other C/EBPs, the expression of C/EBPε is restricted to 
hematopoietic tissues, especially to myeloid cells when they differentiate towards 
granulocytes (Morosetti et al., 1997; Lekstrom-Himes, 2001). For example, the 
expression of C/EBPε is greatly induced by G-CSF during granulocytic differentiation 
of human primary CD34+ cells (Yamanaka et al., 1997b). Second, it has been 
suggested that C/EBPε regulates a rate-limiting step during granulocytic 
differentiation (Yamanaka et al., 1997b; Nakajima and Ihle, 2001). Third, although 
C/EBPε nullizygous mice are normal at birth and are fertile, they fail to produce 
normal neutrophils (Yamanaka et al., 1997a). Thus C/EBPε is thought to play an 
important role in terminal granulopoiesis. The role of C/EBPε was also investigated in 
this study. However, the over-expression of C/EBPε led to only a weak activation of 
the mad1 promoter (Figure 2-10D). In addition, C/EBPε could not be detected on the 
mad1 promoter by ChIP, neither in the absence nor in the presence of G-CSF (Figure 
2-13B). Together these findings suggest that C/EBPε does not play a significant role 
in the regulation of the mad1 gene.  
 
Taken together, the data generated in this study could show: 1) C/EBP binding sites 
are functionally relevant for the activation of the mad1 promoter in response to G-
CSF/G-CSFR signaling; 2) Both C/EBPα and C/EBPβ can transactivate the mad1 
promoter. In response to G-CSF signaling, more likely C/EBPβ, rather than C/EBPα, 
serves as the essential regulator of the expression of the mad1 gene, although the 
mechanism remains unclear. 3) C/EBPε appears to be of minor importance given the 
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modest activation of the mad1 gene and the lack of binding to the promoter in cells. 
   
3.2.3 Repression of mad1 promoter activity in response to G-CSF by Sp 
proteins through the functional SP binding site  
It has been noted that TATA-less promoters are frequently regulated by specific 
transcription factor such as Sp1 and Sp3, which contribute to basal promoter activity 
by interacting and recruiting the basal transcriptional machinery (Suske, 1999; 
Samson and Wong, 2002). Sp1 has often been described as a transcriptional 
activator (Ryu et al., 1999; Suzuki et al., 2000). The over-expression of Sp1 was 
reported to induce transcription of target genes (Won et al., 2002). Indeed, transient 
transfection of plasmids encoding wild type Sp1 were able to induce the activity of 
the mad1 promoter (Figure 2-11B). However, a series of results here indicated that 
Sp1 repressed the activity of the mad1 promoter at the transcriptional level. Most 
importantly, the human mad1 promoter was associated with endogenous Sp1 
constitutively. But, in response to G-CSF Sp1 binding to the promoter was reduced 
(Figure 2-14B). Furthermore, Sp1-C, an Sp1 mutant protein that contains only the 
DNA binding domain but no transactivation domain, was found to relieve the 
repression of the mad1 promoter in a dose-dependent manner (Figure 2-11C). This 
dominant negative experiment suggested that Sp1 may compete for some other 
factor that binds to the GC-box and represses the mad1 promoter in RK13 cells. In 
fact, in certain promoter contexts Sp1 has been reported to be engaged in 
transcriptional repression (Doetzlhofer et al., 1999; Won et al., 2002; Zhao et al., 
2003). This repressive role is achieved through the interaction of Sp1 with HDACs. 
Sp1 may serve as a scaffold to recruit HDAC corepressor complexes to the promoter 
and cause chromatin condensation leading to transcriptional repression. HDACs 
have been found to be part of several transcriptional corepressor complexes, 
including mSin3A, N-CoR and SMRT, which act as transcriptional corepressors of 
several different transcriptional regulators (Alland et al., 1997; Chen and Evans, 1995; 
Heinzel et al., 1997; Sommer et al., 1997). Consistent with this, the expression of the 
mad1 gene was significantly induced when trichostatin A, a histone deacetylase 
inhibitor, was used (data not shown). Thus, it is also possible that Sp1 is involved in 
the regulation of the mad1 gene in vivo through recruiting HDAC corepressor 
complexes. 
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Likewise, Sp3 can also act as either an activator or a repressor in different promoter 
contexts (Suske, 1999; Samson and Wong, 2002). The results in this study showed 
that Sp3 plays a repressive role on the mad1 promoter at the transcriptional level. 
This includes the verification of its binding to the mad1 promoter and the dissociation 
from the promoter in response to G-CSF. It is likely that Sp3 interacts with HDAC2 
(Won et al., 2002), sharing a regulatory mechanism similar to Sp1. In contrast to Sp1, 
the over-expression of Sp3 did not show any induction of the mad1 promoter (data 
not shown), which might argue that there exist different mechanisms between Sp3 
and Sp1 to regulate repression. In fact, it has been shown that the repressive role of 
Sp3 is determined by SUMO modification (Sapetschnig et al., 2002; Ross et al., 
2002). SUMO-modified Sp3 can bind to DNA with similar specificity and affinity as 
unmodified Sp3, but can not activate the target promoter. One explanation for the 
inability of Sp3 to stimulate the mad1 promoter may be that over-expressed Sp3 is 
efficiently sumoylated and therefore kept in a condition that does not allow activation. 
Furthermore it is likely that endogenous Sp3 is sumoylated, occupies the mad1 
promoter and maintains the promoter in a repressed state in the absence of G-CSF 
stimulation. Thus the stimulation seen by Sp1 or Sp1-C might reflect competition of 
Sp3, resulting in release from repression.  
It would be very interesting to know the roles of Sp1 or Sp3 during the regulation of 
the mad1 gene in more detail. Do both transcription factors mediate similar activities 
or are they opposing each other? Since both factors bind to the mad1 promoter it is 
possible that the two are continuously exchanged with Sp3 being dominant (see 
above). What is their role in activating the TATA-less mad1 promoter? Are the GC-
boxes and the associated factors relevant for recruiting basal factors or are they also 
participating in the G-CSF-stimulated activation of the mad1 gene? Answering these 
questions would help to elucidate the mechanisms of regulation of the mad1 gene. In 
addition new insight into the role of the different Sp factors might be obtained. 
Taken together, this study provides evidence for at least one functionally relevant SP 
binding site within the proximal mad1 promoter. In addition, both Sp1 and Sp3 may 
play a role in the regulation of the mad1 gene in response to G-CSF. This may be 
associated with repression since the binding of both proteins is reduced upon 
activation and since histone deacetylation appears to be involved in mad1 promoter 
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regulation. However, the mechanisms that involve Sp proteins in this regulation 
remain unclear.  
3.2.4 Cooperative activation of the mad1 promoter by C/EBP and Sp proteins 
through their functional binding sites 
The cooperation between different families of transcription factors represents a 
general mechanism to coordinate transcriptional responses to specific stimuli in order 
to regulate target genes during the hematopoietic cell development and 
differentiation (Friedman, 2002; Tenen et al., 1997). A number of transcription factors 
have been reported to be able to physically and functionally interact with C/EBP 
proteins that are important for hematopoietic cell differentiation (Diehl et al., 1994; 
Lee et al., 1997; Nagulapalli et al., 1995; Stein et al., 1993; Tahirov et al., 2002). For 
instance, cooperativity between C/EBPβ and Sp1 has been demonstrated in the 
activation of the 2D5 promoter (Lee et al., 1997). This cooperativity requires the 
interaction between the leucine zipper and activation domains of C/EBPβ and the 
serine/threonine- and glutamine-rich activation domains A and B of Sp1. Interestingly, 
although the leucine zipper domain is highly conserved between both C/EBPα and 
C/EBPβ, the C/EBPβ protein containing the leucine zipper domain of C/EBPα could 
not simulate the 2D5 promoter, suggesting that C/EBPα and C/EBPβ differ in their 
capacities to activate the promoter. It may suggest further that Sp1 may not 
cooperate with C/EBPα. In this study, the functionally relevant C/EBP and SP binding 
sites within the mad1 promoter are close on the linear DNA (Figure 2-2; Figure 2-9A), 
offering the possibility for cooperation of C/EBP and Sp proteins. Indeed, mutation of 
both C/EBP and SP binding sites resulted in the loss of almost all activity of both 
mad1 and mintk promoters in response to G-CSF (Figure 2-9). Over-expression of 
C/EBPβ did not result in activation when both CCAAT-boxes and the GC-box were 
mutated in the mad1 promoter (Figure 2-10E). These findings provide evidence for 
the cooperation between these functionally relevant C/EBP and SP binding sites. In 
addition, the increase of CEBPβ and decrease of CEBPα and Sp proteins on the 
endogenous mad1 promoter in response to G-CSF (Figure 2-13B; Figure 2-14B) 
suggest that C/EBP and Sp proteins work together to induce the expression of the 
mad1 gene. However, the mechanisms responsible for the cooperative effects have 
not yet been clarified. It will be important to define whether physical interactions 
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between these proteins exist that could provide part of a mechanistic explanation for 
the cooperativity.  
3.3 G-CSF/G-CSFR signaling transduction pathways relevant for mad1 
expression 
Several signaling pathways, including the JAK/STAT, the RAS/RAF/MAPK and the 
PI3-kinase cascades, have been suggested to be activated by G-CSF/G-CSFR 
(Avalos, 1996; Ihle, 1996). Indeed, STAT3 activation was detected upon treatment of 
RK13 cells transfected with plasmids encoding the G-CSFR or of U937 cells with G-
CSF as shown in this study (Figure 2-12C and Figure 2-17B). In addition ERK1/2 
activation was also observed upon G-CSF treatment (Figure 2-16C, data not shown). 
These findings suggest that at least the JAK/STAT and the RAS/RAF/MAPK signal 
transduction pathways are activated in RK13 and in U937 cells and thus might be 
involved in the regulation of the mad1 gene.  
 
The first finding is that the G-CSFR is necessary for the activation of the mad1 
promoter (Figure 2-15). This requires the membrane-distal region of the receptor 
(Figure 2-15B), especially the presence of four tyrosine residues (Figure 2-15C). In 
accordance with this, it has been shown that the presence of the membrane-distal 
region of the G-CSFR is sufficient to mediate the activation of STATs, to induce gene 
expression, and control different cellular responses depending on the cell type (De 
Koning et al., 1996; Dong et al., 1998; Ward et al., 1999a; McLemore et al., 2001). In 
fact, the G-CSF receptor has been extensively studied before and four tyrosine 
residues (Y704, Y729, Y744, and Y764) have been identified as important positions 
to connect G-CSF/G-CSFR with intracellular signal transduction pathways. It has 
been demonstrated that Y704 and Y744 of the G-CSFR are major docking sites for 
STAT3 (Figure 1-5) (Ward et al., 1999a). Activation of the RAS/RAF/MAPK signaling 
pathway requires the recruitment of other proteins via Y764 of the G-CSFR (De 
Koning et al., 1998; Rausch and Marshall 1997; Ward et al., 1999b), while SOCS3 
binds selectively to the human G-CSFR at Y729. All these interactions require that 
these residues are phosphorylated by JAK kinases. The binding of SOCS3 potently 
inhibits G-CSFR-mediated STAT3 activation and is relevant to inhibit the activity of 
the G-CSFR in an auto-inhibitory feedback loop (Hortner et al., 2002; Croker et al., 
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2004). Thus, it is very likely that JAK/STAT and RAS/RAF/MAPK cascades are 
implicated in the activation of the mad1 gene.  
 
Indeed STAT3 was found to be a strong activator of the mad1 promoter in response 
to G-CSF, while neither STAT1 nor STAT5 showed any induction under the same 
condition (Figure 2-12A). This suggests that not all STAT proteins can mediate the 
expression of the mad1 promoter. In agreement with this, other reports show that 
whereas STAT1 and STAT5 are mainly involved in regulating cell proliferation (Dong 
et al., 1998), STAT3 is essential for growth arrest and differentiation (Maun et al., 
2004; McLemore et al., 2001; Shimozaki, et al., 1997; Tian et al., 1996). In addition, 
two dominant negative mutants of STAT3 were tested to further evaluate this finding. 
One is STAT3dn, which lacks the DNA binding domain; the other is STAT3-Y705F, 
which cannot form homodimers upon signaling and therefore is restricted to the 
cytoplasm, i.e. cannot translocate into the nucleus. STAT3dn resulted in a strong 
repression of the G-CSF-induced expression of the mad1 gene. In combination with 
the fact that there is no typical STAT-binding site within the mad1 promoter (Figure 2-
2), it appears unlikely that STAT3 plays a role as a transcription factor that directly 
binds to the mad1 promoter. Nevertheless, our findings suggest strongly that STAT3 
is a critical mediator of G-CSF singaling. Therefore STAT3 most likely plays a role in 
the regulation of the mad1 promoter through an indirect way. One possibility is that 
STAT3 interacts with other nuclear proteins bound to the promoter, an interaction 
which may need the DNA binding domain of STAT3. STAT3-Y705F also resulted in a 
strong repression of the mad1 gene. In this situation over-expressed STAT3-Y705F 
accumulates in the cytoplasm and interferes with the activation of endogenous 
STAT3. STAT3-Y705F can bind to the active receptor but since it lacks Y705 cannot 
be activated and blocks the receptor for endogenous STAT3. Together these findings 
provide additional evidence for an important role of STAT3 in the activation of mad1.  
 
If STAT3 does not bind directly to a DNA element in the mad1 promoter, the question 
arises how STAT3 is recruited to this promoter. One possibility we considered was 
that STAT3 functions as a cofactor in the setting of the mad1 promoter. We observed 
an interaction between STAT3 and C/EBPβ in response to G-CSF/G-CSFR (Figure 
2-18A), providing evidence for the indirect role of STAT3 in the regulation of the 
mad1 gene. In contrast, an interaction between C/EBPα and STAT3 could not be 
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detected under comparable experimental conditions (data not shown), although such 
an interaction has been reported previously (Numata et al., 2004). To further 
evaluate the possible association between C/EBPβ and STAT3 proteins, an artificial 
system was applied. Dominant negative STAT3 proteins as well as dominant 
negative C/EBPβ inhibited the activity of the chicken myelomonocytic growth factor 
promoter. This promoter contains only C/EBPβ binding sites and its regulation has 
been shown to depend on C/EBP proteins (Figure 2-18B) (Sterneck et al., 1992). 
These findings strongly support the idea that STAT3 was recruited by C/EBPβ to 
mediate the activation of the mad1 gene.  
 
Thus, the data presented here suggest that STAT3, rather than STAT1 or STAT5, is 
necessary and functionally relevant for G-CSF/G-CSFR-mediated activation of the 
mad1 promoter. STAT3 might associate with the mad1 promoter in a C/EBPβ-
dependent fashion to exert its active role. However it is important to note that so far 
we have not been able to demonstrate STAT3 binding to the mad1 promoter by ChIP. 
This may be due to the transient and indirect interaction of STAT3 with DNA.  
 
Other findings in this study support a critical role of the RAS/RAF/MAPK signal 
transduction pathway in the regulation of the mad1 gene by G-CSF. When co-
transfected, an expression plasmid for constitutive active RAS activated the mad1 
promoter in the RK13 cells, albeit only when low amounts of RAS were expressed 
(data not shown). High amounts of RAS resulted in repression, indicating that RAS 
may play a dual role in the regulation of the activity of the mad1 promoter. In addition, 
phosphorylation of ERK1/2 proteins was detectable in both U937 and RK13 cells 
upon stimulation by G-CSF (Figure 2-16C, data not shown). It has been shown 
before that the activation of ERK can result in the phosphorylation and activation of 
C/EBPβ. ERK kinases phosphorylate threonine 218 in the CR7 regulatory region of 
C/EBPβ, inducing a conformational change of the protein. This turns C/EBPβ into an 
activator of transcription (Kowenz-Leutz et al., 1994). Finally, blocking the 
RAS/RAF/MAPK pathway by using the MEK inhibitor PD98059 and p38 MAP kinase 
inhibitor SB202190 reduced the induction of mad1 mRNA in response to G-CSF, 
suggesting that the RAS/RAF/MAPK pathway is involved in the induction of the mad1 
gene. It will be of interest to address whether the activation of C/EBPβ through the 
RAS/RAF/MAPK pathway is required for recruiting activated STAT3 to the mad1 
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promoter. This might provide an interesting model to study the crosstalk between 
these two major, G-CSF/G-CSFR-activated signal transduction pathways.  
  
3.4 Mechanisms of induction of the mad1 gene 
Based on the data generated in this study, several mechanisms of the regulation of 
the expression of the mad1 gene in response to G-CSF can be proposed. One 
mechanism could be that there exists a balance between the activating and the 
repressive effect. Under basic conditions Sp proteins bind to the mad1 promoter and 
recruit HDAC proteins, leading to the condensation of the chromatin structure at the 
promoter and consequently to repression of transcription (Won et al., 2002; Zhang 
and Dufau, 2002). C/EBPα and C/EBPβ also bind to the promoter under non-
inducing conditions. However, without appropriate signals transcription of the mad1 
gene does not occur, potentially because in the absence of signals the C/EBP cannot 
cooperate with Sp proteins or they cannot overcome the postulated Sp-dependent 
repression. Therefore, the transcription of the mad1 gene is off (Figure 3-1A). In 
contrast, in the presence of G-CSF, HDAC proteins might disassociate from the 
mad1 promoter and reduce the repression. The more pronounced recruitment of 
C/EBPβ, the activation of STAT3 and the binding of co-activators and finally RNA 
polymerase II are suggested to stimulate transcription. During this process, C/EBPβ 
might switch from a repressed to an activated form due to phosphorylation (Nakajima 
et al., 1993; Kowenz-Leutz et al., 1994). This modified C/EBPβ has a higher affinity to 
interact with C/EBPα, leading to the formation of C/EBPα/β heterodimers and 
C/EBPβ homodimers. Meanwhile, the binding affinity of these dimers to the promoter 
is increased, leading to a switch of isoforms from C/EBPα to C/EBPβ at the promoter. 
It is then intriguing to speculate that activated C/EBPβ might recruit co-activators, 
including CBP/p300 and SWI/SNF (Figure 3-1B, C), and the basal transcriptional 
apparatus to the mad1 gene promoter to activate transcription. In fact, it is well 
known that CBP/p300 can bind directly to both the basal transcription machinery and 
some transcription factors, including C/EBPs, serving as a bridge to connect these 
two major elements of transcription (Dallas et al., 1997; Kwok et al., 1994; Nakajima 
et al., 1997a; Nakajima et al., 1997b). CBP/p300 can also serve as a platform to 
recruit other co-activators, including HATs such as the p300/CBP-associate factor 
(P/CAF). This complex possesses the ability to modify the N-terminal tail of core 
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histone proteins by adding acetyl groups to conserved lysine residues, eventually 
leading to the opening of the chromatin structure, facilitating the entry of transcription 
factors to promoter regions (Wade et al., 1997). By utilizing either their own HAT 
domain or recruit other HAT domain containing proteins, CBP/p300 are also able to 
acetylate transcription factors directly affecting their activities (Martinez-Balbas et al., 
2000; Spilianakis et al., 2000). In addition, the SWI/SNF chromatin remodelling 
complex that uses the energy of ATP hydrolysis to mobilize nucleosomes and 
remodel chromatin (Roberts and Orkin, 2004) has been reported to interact with the 
N-terminus of C/EBPβ  (Kowenz-Leutz et al., 1999). The recruitment of the SWI/SNF 
complex by C/EBPβ  is necessary to induce the expression of the mim-1 gene  
(Kowenz-Leutz et al., 1999). SWI/SNF proteins can also interact with subunits of the 
RNA pol II holoenzyme (Cho et al., 1998). Thus it is likely that C/EBPβ activates the 
expression of the mad1 gene through the recruitment of two major chromatin 
remodelling complexes, namely p300/CBP and SWI/SNF. More recently, C/EBPβ 
has been reported to interact with the Mediator complex (Mo et al., 2004). 
Interestingly, C/EBPβ binds to the inactive complex that contains CDK8 as well as to 
the active complex possessing CRSP70. RAS signaling promotes the recruitment of 
the active Mediator complex (Mo et al., 2004) further extending the mechanistic 
possibilities of C/EBPβ (Figure 3-1D). The Mediator complexes can act as integrators 
of signals and as molecular bridges between DNA-bound transcription factors and 
the basal transcription apparatus including RNA polymerase II (Bourbon et al., 2004; 
Myers et al., 1998; Sakurai and Fukasawa, 2000). However, whether these C/EBPβ-
dependent possibilities work alone or in a combinatorial way, e.g. with the activated 
STAT3, needs to be determined in the future. 
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Figure 3-1. Models for the regulation of the mad1 gene.  
A) Without G-CSF treatment, both Sp and C/EBP proteins bind to the mad1 promoter. The mad1 gene 
is off because of dominantly acting repressor molecules. Sp proteins are suggested to recruit a 
repressive complex with HDAC activity that inhibits transcription, bound C/EBP proteins may either be 
unable to overcome this repression or are themselves in a repressing state due to the lack of 
activating signals. B, C and D) Upon G-CSF treatment, C/EBP proteins might be activated through the 
RAS/RAF/ERK signal transduction pathway. In turn this may result in the recruitment of co-activator 
complexes, including CBP/p300, SWI/SNF and Mediator, to the promoter to switch on the mad1 
promoter. In addition, HDAC proteins may disassociate from the promoter upon signaling. 
In summary G-CSF activates the JAK/STAT pathway as well as the RAS/RAF/MAPK 
pathway. Generally, these two pathways may regulate a different set of genes whose 
functions dictate the outcome induced by the cytokine in a cell line-specific manner. 
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According to the data presented here, it is conceivable that C/EBPβ is the target at 
which the two signal transduction pathways converge to regulate the mad1 gene. 
Through the activated JAK/STAT pathway, phosphorylated STAT3 dimerizes, 
translocates to the nucleus, where it might form a complex with C/EBPβ (Niehof et al., 
2001; Mink et al., 1997). Thus STAT3 may function as a coactivator in a C/EBPβ-
dependent way. In addition, STAT proteins have been reported to associate with 
other transcription factors, including upstream stimulatory factor 1 (USF1), Sp1, PU.1, 
and C/EBPα (Aittomaki et al., 2000; Look et al., 1995; Muhlethaler-Motter et al., 
1998). These findings suggest additional possibilities how STAT3 might be recruited 
to the mad1 promoter that need to be explored in the future. STAT3 also binds to co-
activators, such as CBP/p300 and NcoA/SRC1a (Giraud et al., 2002; Hiroi and 
Ohmori, 2003; Paulson et al., 1999). This offers the possibility that STAT3 is recruited 
to transcription factors (e.g. C/EBPβ or Sp1) at the mad1 promoter indirectly through 
coactivators. At least some of the above described interactions depend on C/EBPβ 
being activated by the RAS/RAF/MAPK signal transduction pathway (Nakajima et al., 
1993; Kowenz-Leutz et al., 1994; Menard et al., 2002). Taken together, both the 
JAK/STAT and RAS/RAF/MAPK pathways might target the same transcription factor, 
C/EBPβ, one by directly phosphorylating the protein, the other by activating a 
cofactor, STAT3, to achieve the goal of induction of the mad1 gene in response to G-
CSF. Many aspects of this model can be addressed and verified by experiments that 
will allow to evaluate the molecular mechanisms that control the expression of the 
mad1 gene in response to G-CSF signaling.  
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4 Materials and methods 
4.1 Reagents, chemicals and others 
4.1.1 Chemicals  
The chemicals used in this study were from Amersham, Amicon, AppliChem, Baker, 
Biomol, BioRad, Boehringer, Difco, Du Pont, Eurogentech, Falkon, Fermentas, Fluka, 
Gibco BRL, ICN, Invitrogene, Merck, New England Biolabs, Promega, Riedel-deHaen, 
Roth, Santa Cruz, Seromed, Serva, Sigma and Stratagene. The materials needed 
were from Amersham, Beckman, Biozym, Costar, Eppendorf, Falcon, Fuji, Gilson, 
Greiner, Kodak, Macherey-Nagel, Pharmacia, Qiagen, Sarstedt, Schleicher&Schuell 
and Whatman. 
4.1.2 Radiochemicals 
[α32p]ATP Hartman Analytic GmbH (Braunschweig, Germany) 
4.1.3 Cytokines 
G-CSF Chugai Pharmaceutical Co., Ltd, Tokyo, Japan 
TPA     Sigma, USA 
4.1.4 Oligonucleotides 
All oligonucleotides were purchased from MWG-Biotech except for the probes for 
real-time PCR, which were obtained from Biotez. 
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Oligonucleotides for the generation of mutants 
Name Oligo sequences (5’ → 3’) 
C/EBPm1-1 GTGGAGCCCTGAAGCCCTCTCTTCATCGCACAAGTGTAGG 
C/EBPm1-2 CCTACACTTGTGCGATGAAGAGAGGGCTTCAGGGCTCCAC 
C/EBPm2-1 CATTCTTTGGGGGGCTTCATGAGGAACGCGGCCGAAGC 
C/EBPm2-2 GCTTCGGCCGCGTTCCTCATGAAGCCCCCCAAAGAATG 
SPm11 CGCACAAGTGTAGGGTATGGGCATTCTTTGG  
SPm12 CCAAAGAATGCCCATACCCTACACTTGTGCG 
SPm21 CAAGAGAAGGGGCTGGGGTATGGGAGATGGTGAGTC 
SPm22 GACTCACCATCTCCCATACCCCAGCCCCTTCTCTTG 
Oligonucleotides for real time PCR 
Name Oligo sequences (5’ → 3’) 
mad1-probe 6-Fam-TGGACAGCATCGGCTCCACC-Tamra 
mad1-F GAGAAGCTGGGCATTGAGAG 
mad1-R ACGTCGATTTCTTCCCTGTC 
β-gus-probe 6-Fam-TGAACAGTCACCGACGAGAGTGCTGG-Tamra 
β-gus-F CTCATTTGGAATTTTGCCGATT 
β-gus-R CCGAGTGAAGATCCCCTTTTTA 
Oligonucleotides for EMSA 
Name Oligo sequences (5’ → 3’) 
Sp1EMSAFr1 AAGTGTAGGGGCGGGGC 
Sp1EMSARv1 AGAATGCCCCGCCCCT 
Sp1EMSAFr2 AAGGGGCTGGGGCGGGG 
Sp1EMSARv2 CATCTCCCCGCCCCAGCCCCTT 
Other oligonucleotides  
Name Oligo sequences (5’ → 3’) 
Kan001FW GTACTCGAGGTGACATCGTAGC 
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Kan001RV TGACTGGAAGCTTTATCCCCGACTC 
Kan002FWxhoI GTACTCGAGCCGGGCCTTGTC 
Kan002RV TGACTGGAAGCTTCCTCATTGG 
Kan002RVHind3CEBPm TGACTGGAAGCTTCCTCATGAAG 
humad1promSEQP1 CTTGAGGGCAGAAAAAACGCC 
humad1promSEQP2 TGAGGAGCAGCCAGGCTG 
T-vecSeq CGATTAAGTTGGGTAACGCCAG 
pGL for GTATCTTATGGTACTGTAACTG 
pGL rev CTTTATGTTTTTGGCGTCTTCC 
CHIP PRIMERS 
Name Sequence (5’ → 3’) Location Bases Tm/°C Product Size 
F/R3 
GGGCCTTGTCAAGTGTGACC 
ACCCGGAGCAGAGCAGCAGC 
5´/-182  
5´/+42  
20 
20 
61.4 
65.5 
224 
F/Rc 
ATATTGTAGGTGACACAAACTGC 
ATCTCACTTGAAGCTTCCACAG 
3´/+1176  
3´/+1432 
23 
22 
57.1 
58.4 
257 
 
4.1.5 Plasmids 
4.1.5.1 Cloning Vectors 
pGEM-T vector: This vector was  prepared by cutting Promega’s pGEM-5Zf vector 
with EcoR V and adding a 3’ terminal thymidine to both ends, which makes the PCR 
products with an adenosine overhang to be easily cloned into (Promega company).  
4.1.5.2 Reporter Gene Plasmids 
pGL2-Basic-Vector: With an ampicillin-resistant selection, it carries the luciferase 
gene (luc) followed by the SV40 small t antigen intron and early polyadenylation 
[poly(A)] signals and  lacks eukaryotic promoter and enhancer sequences, allowing 
maximum flexibility in cloning putative regulatory sequences (Promega company). 
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pGL2-Humad1-1282: The sequence of putative human mad1 promoter, from -1282 
to +247, was cloned into pGL2-Basic vector with XhoI and BglII enzymes. It was 
made by Kolja Eckert. 
pGL2-Humad1-795: Compared to pGL2-Humad1-1282, it contains the putative 
human mad1 promoter sequence from -795 to +247. It was made by Kolja Eckert. 
pGL2-Humad1-513: Compared to pGL2-Humad1-1282, it contains the putative 
human mad1 promoter sequence from -513 to +247. It was made by Kolja Eckert. 
pGL2-Humad1-385: Compared to pGL2-Humad1-1282, it contains the putative 
human mad1 promoter sequence from -385 to +247. It was made by Alexandra 
Greindl. 
pGL2-Humad1-184: Compared to pGL2-Humad1-1282, it contains the putative 
human mad1 promoter sequence from -184 to +247. It was made by Kolja Eckert. 
pGL2-Humad1-184A#: Compared to pGL2-Humad1-184, the first C/EBP binding site 
was mutated.  
pGL2-Humad1-184B#: Compared to pGL2-Humad1-184, the second C/EBP binding 
site was mutated.  
pGL2-Humad1-184E#: Compared to pGL2-Humad1-184, both C/EBP binding sites 
were mutated.  
pGL2-Humad1-184SPm1#: Compared to pGL2-Humad1-184, the first SP binding site 
was mutated. 
pGL2-Humad1-184SPm2#: Compared to pGL2-Humad1-184, the second SP binding 
site was mutated. 
pGL2-Humad1-184SPm1+2#: Compared to pGL2-Humad1-184, both SP binding site 
were mutated. 
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pGL2-Humad1-184Super: Compared to pGL2-Humad1-184, both C/EBP binding site 
and the first SP binding site were mutated. 
pGL2-Humad1-58: Compared to pGL2-Humad1-1282, it contains putative human 
mad1 promoter sequence from -58 to +247. It was made by Alexandra Greindl. 
pGL2-Humad1+64: Compared to pGL2-Humad1-1282, it contains the putative 
human mad1 promoter sequence from +64 to +247. It was made by Kolja Eckert. 
pGL2-Humad1-400: Compared to pGL2-Humad1-1282, it contains the putative 
human mad1 promoter sequence from -385 to +26 with the high homology region 
between human, mouse and rat. 
pXHmintk-184-58: The portion from -184 to -58 of putative human mad1 proximal 
promoter, was cloned into the pXHmintk-luc (made by Marie Henriksson) vector by 
using XhoI and HindIII enzymes.  
pXHmintk-184-58A#: Compared to pXHmintk-184-58, the first C/EBP binding site 
was mutated. 
pXHmintk-184-58B#: Compared to pXHmintk-184-58, the second C/EBP binding site 
was mutated. 
pXHmintk-184-58E#: Compared to pXHmintk-184-58, both C/EBP binding sites were 
mutated. 
pXHmintk-184-58SPm1#: Compared to pXHmintk-184-58, the first SP binding site 
was mutated. 
pXHmintk-184-58Super: Compared to pXHmintk-184-58, both C/EBP binding sites 
and SP binding site were mutated. 
6D cMGF-luc: The sequence of chicken myelomonocytic growth factor promoter from 
region -82 to -51 was cloned into the pXP2 vector (Nordeen et al., 1988), which 
contains two C/EBP binding sites (Sterneck et al., 1992). 
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14D cMGF-luc: The sequence of chicken myelomonocytic growth factor promoter 
from region -82 to -51 was cloned into the pXP2 vector, which both C/EBP binding 
sites were mutated (Sterneck et al., 1992). 
4.1.5.3 Expression Vectors  
pEQ176: The immediate early cytomegal-virus (CMV)-promoter constitutively 
expresses β-galactosidase in eukaryotic cells (Firzlaff et al., 1991). 
pLNCX-GCSF/R: Human G-CSFR cDNA was cloned into the retroviral vector LNCX. 
It is a kind gift from Prof. Welte (Pediatric Hematology and Oncology, Hannover 
Medical School, Germany). 
pLNCX-GCSF/RΔ649: Human G-CSFR cDNA encoding the amino acids from 1 to 
649 was cloned into the retroviral vector LNCX. 
pLNCX-GCSF/RΔ670: Human G-CSFR cDNA encoding the amino acids from 1 to 
670 was cloned into the retroviral vector LNCX. 
pLNCX-GCSF/RΔ685: Human G-CSFR cDNA encoding the amino acids from 1 to 
685 was cloned into the retroviral vector LNCX. 
pLNCX-GCSF/RmA: Compared to pLNCX-GCSF/R, only tyrosine 704 remained 
unchanged within the cytoplasmic part of G-CSFR, the other three tyrosines (729, 
744, 764) were mutated into phenylalanine (Hermans et al., 2003). 
pLNCX-GCSF/RmB: Compared to pLNCX-GCSF/R, only tyrosine 729 remained 
unchanged within the cytoplasmic part of G-CSFR, the other three tyrosines (704, 
744, 764) were mutated into phenylalanine (Hermans et al., 2003). 
pLNCX-GCSF/RmC: Compared to pLNCX-GCSF/R, only tyrosine 744 remained 
unchanged within the cytoplasmic part of G-CSFR, the other three tyrosines (704, 
729, 764) were mutated into phenylalanine (Hermans et al., 2003). 
pLNCX-GCSF/RmD: Compared to pLNCX-GCSF/R, only tyrosine 764 remained 
unchanged within the cytoplasmic part of G-CSFR, the other three tyrosines (704, 
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729, 744) were mutated into phenylalanine (Hermans et al., 2003). 
pLNCX-GCSF/Rm0: Compared to pLNCX-GCSF/R, all four tyrosines were mutated 
to phenylalanine (Hermans et al., 2003). 
pLNCX-GCSF/R704F: Compared to pLNCX-GCSF/R, only tyrosine 704 was mutated 
to phenylalanine (Hermans et al., 2003). 
pLNCX-GCSF/R729F: Compared to pLNCX-GCSF/R, only tyrosine 729 was mutated 
to phenylalanine (Hermans et al., 2003). 
pLNCX-GCSF/R744F: Compared to pLNCX-GCSF/R, only tyrosine 744 was mutated 
to phenylalanine (Hermans et al., 2003). 
pLNCX-GCSF/R764F: Compared to pLNCX-GCSF/R, only tyrosine 764 was mutated 
into phenylalanine (Hermans et al., 2003). 
pCB6+-C/EBPα: The cDNA of C/EBPα was cloned into pCB6+ vector by using HindIII 
and EcoRI enzymes. The expression of C/EBPα is under the control of the CMV 
promoter (Oelgeschlager et al., 1996). 
pCB6+-C/EBPβ: The cDNA of C/EBPβ was cloned into pCB6+ vector by using HindIII 
and EcoRI enzymes. The expression of C/EBPβ is under the control of the CMV 
promoter (Oelgeschlager et al., 1996). 
pcDNA3-C/EBPε: A 1.2-kb cDNA encoding full-length human  C/EBP-epsilon was 
cloned into pcDNA3 under the control of CMV promoter (Verbeek et al., 1999).  
pCI-neo-HA-SP1: Full length Sp1 cDNA was cloned into pCI vector. It was a kind gift 
from H. Rotheneder (Wien, Austria). 
pCI-neo-HA-SP1-N: This construct can express the N terminal part of Sp1, from 
amino acid 8 to 618. It was a kind gift from H. Rotheneder (Wien, Austria). 
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pCI-neo-HA-SP1-C: This construct can express the C terminal part of Sp1, from 
amino acid 619 to 785. It was a kind gift from H. Rotheneder (Wien, Austria). 
pCAGGS-neo-HA-STAT1: The cDNA encoding full-length human STAT1 was cloned 
into pCAGGS vector. It is a kind gift from Prof. Heinrich (Aachen, Germany). 
pCAGGS-neo-HA-STAT3: The cDNA encoding full-length murine STAT3 was cloned 
into pCAGGS vector. It is a kind gift from Prof. Heinrich (Aachen, Germany). 
pCAGGS-neo-HA-STAT3F: Compared to the wild type STAT3 protein expressed by 
pCAGGS-neo-HA-STAT3, the tyrosine residue at 705 was mutated into 
phenylalanine. It is a kind gift from Prof. Heinrich (Aachen, Germany). 
pCAGGS-neo-HA-STAT3D: Compared to the wild type STAT3 protein expressed by 
pCAGGS-neo-HA-STAT3, this construct can not express the DNA binding domain. It 
is a kind gift from Prof. Heinrich (Aachen, Germany). 
pmusSTAT3: The cDNA encoding murine STAT3 was cloned into Rc/CMV vector 
with Not I and Apa I enzymes (Zhong Z et al., 1994). 
pECESTAT5α: The cDNA encoding STAT5α was cloned into pECE vector. It is a 
kind gift from Prof. Heinrich (Aachen, Germany). 
pECESTAT5β: The cDNA encoding STAT5β was cloned into pECE vector. It is a 
kind gift from Prof. Heinrich (Aachen, Germany). 
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4.1.5.4  Antibodies 
Antigen Company Cat.Nr. Use 
Cytochrom C Santa Cruz Biotechnology Sc-7159 ChIP 
Pol(C21) Santa Cruz Biotechnology Sc-900 ChIP 
AcH4 Upstate #06-598 ChIP 
AcH3 Upstate #06-866 ChIP 
H3-K4 Upstate #07-030 ChIP 
C/EBPα Santa Cruz Biotechnology Sc-61 ChIP 
C/EBPβ Santa Cruz Biotechnology Sc-746 ChIP, IP, WB 
C/EBPεC22 Santa Cruz Biotechnology Sc-158 ChIP 
ERK1 (C16) Santa Cruz Biotechnology Sc-93 ChIP, WB 
ERK(E4) Santa Cruz Biotechnology Sc-7383 WB 
STAT3-P Cell Signaling #9131 WB 
STAT3(C20) Santa Cruz Biotechnology Sc-482 CHIP 
STAT3 Becton, Dickinson and Company 610189 WB  
SP3(D20) Santa Cruz Biotechnology Sc-482 CHIP 
SP1(PEP2) Santa Cruz Biotechnology Sc-59 CHIP  
SP1(rabbit) A kind gift from Pro. Suske G 
(Marburg, Germany)  CHIP 
actin Sigma A2066 WB 
HA(3F10) E.Kremmer (Munich, Germany)   
HRP-conjugated anti-
mouse-IgG Jackson ImmunoResearch Labs 
#111-035-
146 WB 
HRP-conjugated anti-
rat-IgG Jackson ImmunoResearch Labs 
#111-035-
068 WB 
HRP-conjugated anti-
rabbit-IgG Jackson ImmunoResearch Labs 
#111-035-
144 WB 
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4.1.6 Prokaryotic cells and the culture 
4.1.6.1 E. Coli strains 
XL10 gold (Invitrogen): TetrD (mcrA) 183, D(mcrCB-hsdSMR-mrr)173, endA1, 
supE44 thi-1, recA1, gyrA96, relA1, lac, Hte [F’proAB lacIqZDM15 Tn10 (Tetr) Amy 
Camr]a 
TOP/10/P3 (Invitrogen): F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 
recA1 araD139 ∆(araleu) 7697 galU galK rpsL endA1 nupG P3: KanR AmpR (am) 
TetR (am) 
DH5α (Invitrogen): F- φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, 
mk+) phoA supE44 thi-1 gyrA96 relA1- 
4.1.6.2 Medium 
agar plate      LB medium 
(Amp-resistant)     1.5% (w/v) bacto Agar 
100 µg/ml ampicillin 
agar plate     LB medium 
(Kana-resistant)     1.5% (w/v) bacto Agar 
100 µg/ml kanamycin 
 
LB medium      1% (w/v) trypton 
(pH7.0)      0.5% (w/v) yeast extract 
1% (w/v) NaCl 
 
4.1.7 Eukaryotic cells and culture 
4.1.7.1 Eukaryotic cells 
HEK293    ATCC CRL-1573 
U937   a kind gift from Lars-Gunnar Larsson 
HL60   ATCC CCL-240 
RK13   ATCC CCL-37 
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4.1.7.2 Culture conditions 
All cell culture medium contains 1% (w/v) penicillin/streptomycin. 
HEK293      DMEM with 10% (v/v) FCS 
RK13       MEM with 10% (v/v) FCS 
U937       RPMI 1640 with 10% (v/v) FCS 
HL60       RPMI 1640 with 10% (v/v) FCS 
4.1.7.3 Materials for cell culture 
DMEM (Gibco)     with 4.5 g/l glucose 
MEM (Gibco)      with 4.5 g/l glucose 
RPMI 1640 (Gibco) 
PBS       140 mM NaCl 
2.6 mM KCl 
2 mM Na2HPO4 
1.45 mM KH2PO4 
 
Penicillin/Streptomycin (Seromed)  10.000 units/10.000 µg/ml 
Trypsin/EDTA (Seromed)    0.5/0.02% (w/v) in PBS 
FCS (Gibco)      fetal calf serum 
Cell culture plate (Falcon)     diameter 6, 10 cm 
Cell culture bottle (Falcon)     volume 100, 250, 1000ml 
1 ml cryovial (Nalgene) 
4.1.7.4 Cryopreservation 
106–107 cells were trypsinized and collected with medium, centrifuged at 4°C by 1250 
rpm for 5 minutes. Cell pellets were resuspended in 1 ml 10% DMSO/FCS. The 
suspension was transferred into cryovials, kept at -20°C for 0.5 h and -80°C for 
overnight, then stored in a -150°C refrigerator. 
4.2 General Molecular Techniques 
4.2.1 Polymerase Chain Reaction (PCR)  
Polymerase Chain Reactions (PCR) were performed with Taq DNA Polymerase, 
dNTPs, template DNA, and specifically designed primers. Components were added 
to achieve the final reaction concentration as described in the PCR enzyme 
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manufacturer’s protocol. Reactions were typically performed for between 25 and 35 
cycles in a thermocycler.  
4.2.2 Site Directed Mutagenesis 
All mutant plasmids were generated using the QuickChange® site directed 
mutagenesis protocol (Stratagene, Heidelberg, Germany) with complementary 
primers spanning the mutation site.  
 
4.2.3 Restriction digestion of plasmid DNA 
Typically 0.5~1 µg DNA was digested by using 1× optimal buffer and 0.5 µl each 
enzyme in a 20 µl volume, and incubated at 37°C for 2 h. The restriction digestion 
was analyzed by agarose gel electrophoresis. 
4.2.4 DNA agarose gel electrophoresis and extraction 
DNA-loading buffer     50 mM Tris-HCl, pH 8 
50 mM EDTA 
50% (v/v) glycerin 
0.25% (w/v) BPB 
0.25% (w/v) XC 
 
TBE        89 mM Tris-HCl pH 8 
89 mM boric acid 
2 mM EDTA 
DNA ladder “1kb” (Fermentas) 
QIAquick Gel Extraction Kit (Qiagen) 
 
Analytical and preparative gel electrophoresis of double-stranded DNA fragments 
was performed in 1% agarose gels supplemented with ethidium bromide (0.1 mg/ml). 
DNA fragment sizes were determined by using a DNA marker. Bands were visualized 
using a UV transilluminator at 302 nm. In preparative electrophoresis the desired 
DNA fragment was excised with a sterile scalpel and extracted with the QIAquick Gel 
Extraction Kit (Qiagen). 
Materials and methods  88 
 
 
4.2.5 DNA ligation 
After the vector and insert DNA had been prepared, the concentration ratio of both 
DNA fragments was estimated by agarose gel electrophoresis. Using the appropriate 
molar ratio of vector: insert (1:3), the ligation system was set up as the follows: 
Vector DNA      20-50 ng 
Insert DNA      X ng 
T4 DNA ligase     1 µl 
Ligase 10 × buffer     1 µl 
Nuclease-free water to final volume  10 µl 
 
The ligation reactions were incubated at 4°C for overnight. Afterwards the ligated 
DNA was transformed into appropriate competent cells.  
4.2.6 Transformation  
200 µl of competent cells were mixed with 10 µl of ligated DNA in a 1.5 ml reaction 
tube and incubated on ice for 20 min. Heat shock was performed at 42°C in a water 
bath for 90 seconds; after that bacteria were immediately placed on ice for further 2 
min, 0.4 ml LB medium was added and the cells were shaken at 200 rpm on a 
thermal block for 1 h at 37°C. Finally cells were plated on agarose plates containing 
the appropriate antibiotic and incubated at 37°C for overnight. 
4.2.7 Plasmid mini-preparation and maxi-preparation 
The Qiagen mini-preparation kits and maxi-preparation kits were used for the small 
and large scale purification of plasmid DNA respectively according to the supplier’s 
instruction.  
4.2.8 Quantification of nucleic acids 
Quantification of nucleic acids was done by UV spectrophotometry. The reading at 
260 nm allows calculation of the concentration of nuclei acids in the sample. An OD 
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of 1 corresponds to ~50µg/ml double stranded DNA. The ratio between the reading at 
260 and 280 nm provides an estimate for the purity of nucleic acids. The ratio of 
A260/A280 should be in the range of 1.8-2.0.  
4.2.9 DNA Sequencing 
For verification, all mutated plasmids were sequenced by MWG BIOTECH. 
4.3 Real time quantitative reverse transcriptase PCR 
The real time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) 
is the most sensitive and accurate method to detect the low abundance mRNA from 
cells, body fluids and tissues. This powerful method allows the direct detection of 
PCR products during the log phase of the reaction through the presence of a dual-
labelled fluorogenic probe, measuring the increase in fluorescence emission. It was 
used here to check the mRNA expression of human mad1 gene from myeloid and 
primary cells. 
4.3.1 Sample preparation 
On the day of harvesting, cells were split into different 6cm plates with 1 x 107cells/ 5 
ml medium (without FCS) for more than 3 h. Then the cells were treated with G-CSF 
at the final concentration of 10 ng/ml for the times indicated. If inhibitors were used, 
they were added 40 min prior to G-CSF. Subsequently the cells were collected, 
centrifuged and washed with cold PBS. Afterwards, the pellets were ready for direct 
RNA isolation or stored at -70°C. 
4.3.2 Isolation of RNA  
Total RNA was made by using the RNeasy Mini Kit (Qiagen) according to the 
protocol. RNase Free DNase Set (Qiagen) was applied during the RNA purification to 
avoid contamination with genomic DNA. The concentration of RNA was determined 
by UV spectrophotometry. 
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4.3.3 cDNA synthesis 
Reverse transcription of RNA was made in a final volume of 20 µl containing 1 x RT-
PCR buffer, 10 units of RNasin RNase inhibitor (Promega Corp., Madison, WI), 5 mM 
dNTPs, 4 units of Omniscript Reverse Transcriptase (Omniscipt RT Kit, Qiagen), 0.2 
µg random hexamers (Amersham Biosciences) and 1.5 µg of total RNA. The 
samples were incubated at 37°C for 1 h and reverse transcriptase was inactivated by 
heating at 95°C for 5 min and cooling at 4°C for 5 min. The samples were ready for 
real time PCR or stored at -20°C. 
4.3.4 Real time PCR 
cDNA was amplified and quantified using TaqMan Universal PCR reagents from PE 
Applied Biosystems (Darmstadt, Germany). Briefly, the cDNAs for mad1 and internal 
control β-glucuronidase were amplified using specific probes and primers (detailed 
sequences shown in 3.1.4 Oligonucleotides). The PCR reaction was performed in a 
final volume of 25 µl containing 2.5 µl cDNA, 900 nM of each primer, 250 nM of 
TaqMan probe (Biotez, Berlin, Germany) and 12.5 µl TaqMan Universal Master Mix 
PCR buffer with ABI 7000 instrument. After denaturing for 10 min at 95°C, 
amplification was performed for 40 cycles of 15 sec at 95°C, and a combined 
annealing/extension step of 60 sec at 60°C using the ABI prism 7000 (PE Applied 
Biosystems, Darmstadt, Germany).  
For quantification of gene expression the comparative CT method recommended for 
the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, 
Darmstadt, Germany) was used. Initially, a validation experiment was performed to 
demonstrate equal transcription efficiencies for mad1 (target gene) and β-
glucuronidase (reference gene). Then, the PCR cycle number CT was determined at 
which an increase in probe fluorescence above the baseline signal can first be 
detected. ΔCT was calculated by subtracting the cycle number CT obtained for β-
glucuronidase from that of mad1. Triplicate ΔCT values were averaged for each 
sample. Finally, the fold induction of mad1 mRNA was calculated as follows: first, the 
averaged ΔCT value of three control samples was subtracted from that of treated 
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samples at each time point to get the value of ΔΔCT, then the 2-ΔΔCT formula was 
applied. 
4.4 Chromatin Immunoprecipitation (ChIP) 
4.4.1 Fixation 
 Cultured cells were centrifuged in a 500 ml cup, 440 x g, 5 min, 4°C 
 Cells were resuspended at 106 cells /ml with cold medium without FCS  
 Cell suspension were swirled slowly with a magnetic mover on ice 
 1/10 volume of the fixation solution with 11% formaldehyde was added slowly to 
the suspension for 20 min 
 The fixation was stopped by adding glycine with a final concentration of 0.125 M, 
mixed well until all glycine was soluble 
 Cells were centrifuged and suspended in ice-cold PBS at 108 cells /40 ml 
 Cells were centrifuged and suspended in washing solution A with protein 
inhibitors, 108 cells /5 ml, RT, 15 min, on a tilting shaker 
 Cells were centrifuged and suspended in washing solution B with protein 
inhibitors, 108 cells /5 ml, RT, 15 min, on a tilting shaker 
 Cells were centrifuged and suspended in ice-cold CHIP RIPA buffer with protein 
inhibitors, 2.5×107 cells /ml 
 Lysates were sonicated in an aliquot of maximal volume of 5 ml in a 15 ml tube. 
Branson Sonifier, cell disrupter B15, 0.5 cycle, 50% output, microtip with 2.0~3.0, 
3 x 2 min, on ice 
 Aliquots were centrifuged in 2 ml Eppendorf tubes, maximal speed, 4°C, 30 min 
 The supernatant was stored at -70°C or used immediately for the IP 
 
4.4.2 Immunoprecipitation 
 2 µg of antibody was added into 1ml CHIP RIPA lysate, 4°C, overnight, on a 
roller 
 Protein A/G Sepharose beads were washed with 1ml CHIP RIPA buffer, twice, 
2000 rpm, 1 min, 15~20 µl beads in 100 µl CHIP RIPA buffer for each IP 
 The beads were incubated with the lysates for 60 min, 4°C on a roller 
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 The beads were washed with 1.5 ml buffers as following, RT, 10 min 
CHIP RIPA buffer    twice 
High Salt buffer     twice 
CHIP RIPA buffer    twice 
TE buffer      twice 
 The beads were eluted with 52 µl elution buffer, RT, 10 min, mixing 1000 rpm 
 50 µl supernatant of each tube was transfered into new tube   
 
4.4.3 DNA Preparation 
 TE buffer   149 µl     149 µl 
RnaseA (10mg/ml)  1 µl     1 µl 
Eluate    50 µl  total chromatin 20 µl 
200 µl  Elution buffer 30 µl 
200 µl 
37°C 30 min 
 20 mg/ml proteinase K 5 µl and 20% SDS 2,25 µl (only to the tubes containing 
total chromatin) were added  
 37°C overnight 
 66°C overnight 
 1 volume Phenol/Chloroform/Isoamylalkohol (PIC=25/24/1) extraction was added, 
vortexed, and centrifuged for 10 min at 14000 rpm, RT 
 200 µl supernatant was taken to a new tube, adding following mixture  
1/10 Vol. 3 M NaAc. pH 5,2 20 µl 
20 µg Glycogen   1 µl 
3 Vol. EtOH              600 µl 
      -20°C, overnight 
 4°C, 14000 rpm, 20 min 
 70% EtOH 500 µl was added into each tube, 4°C, 14000 rpm, 10 min 
 The pellets were dryed in the 30°C heatblock 
 Pellet from the eluted sample was dissolved in 50 µl TE at 4°C 
Pellet from total chromatin sample was dissolved in 20 µl TE at 4°C  
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4.4.4 PCR 
 PCR reaction 
10 x Hotstar PCR buffer (Qiagen)  3 µl 
dNTP Mix (4 x 2 mM, final 4 x 0.2mM) 3 µl 
Primer Mix (10 µM each, final 1µM)  3 µl 
PCR water     18 µl 
Hotstar Taq Polymerase (5u/l)  0.5 µl 
DNA template     2.5 µl 
       30 µl 
 PCR conditions 
95°C      15 min 
28~34 cylces, depending on the targets 
94°C       20 s 
60°C      20 s 
72°C      20 s 
72°C      7 min 
4°C       overnight 
 Gel 
PCR product     15 µl 
10 x loading buffer    2 µl  
2% agarose/TAE/EtBr Gel  
 
4.4.5 Reagents 
 Fixation solution    0.1 M NaCl 
       1 mM EDTA 
       0.5 mM EGTA 
       50 mM Tris-HCl, pH 8 
       = Stock-solution 
       37%Formaldehyde (added before use) 
 Washing solution A    0.25% Triton X 100 
       10 mM Tris-HCl, pH 8 
       10 mM EDTA 
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       0,5mM EGTA 
       Protein inhibitors (added before use) 
 Protein inhibitors    0.5% Aprotinin 
       Pefa-Block (stock=500×) 
 Washing solution B    0,2 M NaCl 
       10 mM Tris-HCl, pH 8 
       1 mM EDTA 
       0.5 mM EGTA 
       Protein inhibitors (added before use) 
 TE Buffer     10 mM Tris-HCl, pH 7.5 
       1 mM EDTA 
       RNase-free H2O 
 Elution Buffer     2% SDS/TE buffer 
 High Salt Buffer    2 M NaCl 
       10 mM Tris-HCl, pH 7.5 
       1% NP40 
       0.5% DOC 
       1 mM EDTA 
 CHIP RIPA Buffer    150 mM NaCl 
       10 mM Tris-HCl, pH 7.5 
       1% NP40 
       0.1% DOC 
       1 mM EDTA 
       0.5% Aprotinin 
 Phenol/IAA/Chloroform(25:1:24)  
 
4.5 Nuclear extraction and electrophoretic mobility shift assays (EMSA)  
4.5.1 Nuclear extraction 
 U937 cells were stimulated with 10 ng/ml G-CSF for 0, 0.5 h, 1 h, and 2 h  
 U937 cells were washed twice with cold PBS (containing 100 µM Na3VO4)  
 Pellets were resuspended in 400 µl buffer A on ice for 15 min, vortexed 10 sec 
 Centrifugation, maximal speed, 10 sec  
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 The nuclei were collected and resuspended in 40 µl buffer C for 30 min on ice  
 Centrifugation, maximal speed, 10 min, 4°C  
 Supernatants containing the nuclear extracts were frozen and stored at -80°C. 
The protein concentration of the nuclear extracts was determined with the 
BioRad reagent (Bio-Rad, München, Germany) 
 
4.5.2 Oligo hybridization and labeling 
The two single strand oligos were annealed before labeling. 
 Annealing 
each oligonucleotide (100 pmol/ml)    10 µl 
5 M NaCl       1.5 µl 
ddH2O        28.5 µl 
95° C for 10 sec and cooled slowly down for 2~3 h 
 Labelling and purification 
DNA (2.5 pmol/µl)      1 µl  
10 x Restriction buffer M (Boehringer Mannheim) 6 µl  
dCTP (0.5 mM)      1 µl  
dGTP (0.5 mM)      1 µl  
dTTP (0.5 mM)      1 µl  
H2O       45.5 µl 
[α 32P] dATP      2 µl  
Klenow Enzyme (5 U)     2.5 µl  
37°C for 30min, then purified with QIAquick Nucleotide Removel Kit (Qiagen). 
4.5.3 Electrophoretic mobility shift assays (EMSA)          
 8 µg nuclear extract was incubated with 2 µg antibodies, 4°C, 20 min  
 The antibody/nuclear extract complex was incubated with a surplus of double-
strands [32P] labelled SP probe1: 5’-AAGTGTAGGGGCGGGGC-3’ and probe 2: 
5’- AAGGGGCTGGGGCGGGG -3’ for binding SP proteins in gel shift incubation 
buffer, RT, 20 min 
 The protein/DNA complexes were separated on a 4.5% polyacrylamide gel at 20 
V/cm for 4 h 
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 Gels were fixed for 1 h, dried, and autoradiographed 
4.5.4 Reagents 
 Buffer A 
Hepes-KOH, pH 7.8    10 mM 
MgCl2      1.5 mM  
KCl      10 mM 
DTT      0.5 mM 
PMSF      0.2 mM 
Na3VO4      1 mM 
 Buffer C 
Hepes-KOH, pH 7.8    20 mM 
MgCl2      1.5 mM  
NaCl      420 mM 
EDTA      0.2 mM 
Glycerol     25 %v/v 
DTT      0.5 mM 
PMSF      0.2 mM 
Na3VO4      1 mM 
 5 x DNA binding buffer 
Hepes-KOH, pH 7.8    50 mM 
MgCl2      25 mM 
EDTA      5 mM 
Glycerol     50 %v/v 
 Gel shift incubation buffer for one sample (final volume: 20µl) 
Nuclear extract     8 µg 
5 x DNA binding buffer   4 µl 
1 M DTT    0.1 µl 
200 mM PMSF     0.2 µl 
1 mg/ml poly (dI-dC)    1 µl 
10 mg/ml BSA     2 µl 
ddH2O      x µl 
 4.5% polyacrylamide gel 
40% Acrylamide mix    6.75 ml 
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86% Glycerol     5.25 ml 
5xTBE      3 ml 
H2O      45 ml 
10% APS     400 µl 
TEMED      40 µl 
 Running buffer 
0.25 x TBE 
 Fixation buffer 
methanol     10% 
acetic acid     10% 
H2O      80% 
4.6 Reporter gene assay 
Genetic reporter systems have contributed greatly to the study of eukaryotic gene 
expression and regulation, and were especially used as an indicator of transcriptional 
activity in cells. The transient transfection of adherent cells was done here with the 
calcium-phosphate method. The efficiency of this transfection was approximately 5-
10% and always normalized by measuring β-galactosidase activity. 
4.6.1 Transient transfection 
 The day before transfection, the cells were split, 1.5 x 105 /6 cm plate  
 The day of transfection, 2 h before transfection, the medium was replaced by 3 
ml fresh complete medium per plate 
 200 µl CaCl2 was mixed briefly with 7~10 µg DNA (including 2 µg reporter vector, 
0.5 µg β-Galactosidase and 1 µg G-CSFR expression vector) 
 200 µl 2x HEBS-buffer was added dropwise, mixed well and kept at room 
temperature for 10 min. Then the mixture was added dropwise directly into the 6 
cm plate 
 The plates were put immediately in the incubator (37°C, 5% CO2)  
 After 6-10 h, the plates were washed with HEPES buffer twice, and then 3 ml 
fresh medium was added 
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 24 h after transient transfection, G-CSF was added into the induced-groups with 
a final concentration of 10 ng/ml for 6 h 
4.6.2 Luciferase assay and β-Galactosidase assay 
 The cells was washed twice with cold PBS 
 The cells was lysed with 300 µl extraction buffer, 4°C, 10 min 
 The cells was scraped and centrifuged, 4°C, 10 min, maximal speed 
 For the luciferase assay, 20 µl supernatant was mixed with 100 µl measuring 
buffer in a 96-well plate. 30 µl luciferin solution was injected and the luciferase 
activity was measured by the Biolumator automatically 
 For the β-Galactosidase assay, 20 µl supernatant was mixed with 100 µl Z buffer 
and 25 µl ONPG in a 96-well plate and incubated at 37°C for 5-10 min.  250 µl 1 
M Na2CO3 was added to stop the reaction when the colour of mixture turned 
yellow. The β-galactosidase activity was measured photometrically at 405 nm 
with the Biolumator (Victor) 
 Assays were carried out in triplicate and the experiments were repeated three 
times 
4.6.3 Reagents 
 2 x HEBS buffer      274 mM NaCl 
42 mM HEPES 
9.6 mM KCl 
1.5 mM Na2HPO4 pH 7.1 
 HEPES buffer      142 mM NaCl 
10 mM HEPES 
6.7 mM KCl pH 7.3 
 250 mM CaCl2 
 extraction buffer      25 mM Tris-HCl, pH 7.8 
2 mM EDTA 
10% (v/v) glycerol 
1% (v/v) Triton X-100 
2 mM DTT 
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 Z-buffer        60 mM Na2HPO4 
40 mM NaH2PO4 
10 mM KCl 
1 mM MgSO4 
50 mM β-mercaptoethanol 
 measuring buffer      25 mM glycylglycin 
15 mM MgSO4 
5 mM ATP, pH 7 
 stop reagent      1 M Na2CO3 
 substrates      25 mM luciferin solution 
4 mg/ml ONPG  
4.7 Detection of the proteins 
4.7.1 Co-transient transfection 
The transfection method was similar to that used in the reporter gene assay. 
However, the total DNA amount was about 20~25 µg (including 3 µg G-CSFR, 7 µg 
STAT3 and 7 µg C/EBPβ?expression vectors) as 10 cm plates were used. In addition, 
the transfection time was shorter (about 4~5h) due to the different cell line used. 
Before harvesting, the cells were starved for at least 3 h.  
4.7.2 Preparation of cell lysates 
Cells were lysed in 300 µl F-buffer/Co-IP buffer for 20 min at 4°C. Lysed cells were 
scraped and pipetted into 1.5 ml Eppendorf tubes. After vortexing for 45 sec and 
centrifuging at maximal speed for 10 min at 4°C, the supernatant was transferred into 
new tubes for immediate experiments or stored at –80°C. 
 
4.7.3 Immunoprecipitation (IP) 
To cell lysates, 20 µl of protein A or G agarose beads (50% slurry) as well as 2 µg 
antibody for each IP were added and incubated on a rotating wheel at 4°C for 2 h. 
After centrifugation, the supernatants were removed. The precipitates were washed 
for three times with Co-IP buffer and resuspended in 30 µl 4 x SDS-sample buffer, 
boiled at 95°C for 5 min and stored at –20°C. 
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4.7.4 SDS-PAGE 
Protein separation under denaturating conditions was done according to the size of 
the protein in a 7.5 -12.5% polyacrylamide (PAA) gel. The protein samples were 
directly loaded onto the SDS-PAGE. 
4.7.5 Immunoblotting 
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes 
in 1 x semi-dry-buffer. Blots were blocked with 5% nonfat milk for 30 minutes at room 
temperature in PBST and incubated with the primary antibody (overnight at 4°C) in 
PBST. Membranes were washed with PBST and incubated with peroxidase-
conjugated secondary antibody (1 h at RT). After three washing steps for 10 min, 
proteins were detected by using the chemiluminescence kit ECL (Amersham, 
Piscataway, NJ) followed by exposure to X-ray films or detected with LAS3000 (Fuji 
Photo Film Co., Ltd, Japan). 
4.7.6 Determination of protein concentration by Bradford method 
Protein content determination was performed according to the protocol attached (Bio-
Rad, München, Germany). The Bio-Rad protein assay is based on the color change 
of a dye in response to various concentrations of protein. To create the standard 
curve, 0-12 µg BSA was dissolved in 800 µl water and 200 µl 5 × Bio-Rad reagent 
and incubated at RT for 5 min. The OD595 was plotted versus the concentration of 
standards. For each sample, 3 µl lysates were added to 1 ml 1 × Bio-Rad and the 
absorption was measured. The concentration (µg/µl) of the sample is the value of 
OD595 multiplied with factor 5.44. 
4.7.7 Reagents 
F-buffer was used for the analysis of protein from cell line or transient transfected cell. 
 Frackelton buffer (F-buffer)    50 mM HEPES, pH 7.4 
50 mM NaCl 
30 mM Na4P2O7 
Materials and methods  101 
 
100 µM Na3VO4 
10% glycerol 
0.2% (w/v) Triton X-100 
1mM NaF 
1 mM pefa-block 
5 U/ml α-macroglobulin 
2.5 U/ml pepstatin A 
2.5 U/ml leupeptin 
0.15 mM benzamidin 
 
 SDS-sample buffer     160 mM Tris-HCl, pH 6.8 
20% (v/v) glycerin 
10% (w/v) SDS 
0.25% (w/v) BPB 
100 mM β-mercaptoethanol 
 
 loading buffer      50 mM Tris-Base 
380 mM glycin 
0.1% (w/v) SDS 
 
 protein ladder     “prestained protein ladder”, about 10 – 
180 kDa, from MBI-Fermentas 
(#SM0671) 
 
 10 x semi-dry-buffer     250 mM Tris-base 
1.92 M glycine 
pH 8.3-8.8 
 
 1 x semi-dry-buffer    10 x semi-dry-buffer 
20% methanol 
mixed freshly 
 
 blocking buffer     PBS 
0.1% (v/v) Tween-20 
5% (w/v) nonfat milk 
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 wash buffer (PBST)    PBS 
0.1%(v/v) Tween-20 
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Abbreviations 
Ab  antibody 
Amp   ampicillin 
APS   ammonium persulfate 
ATCC  american type culture collection 
ATP   adenosintriphosphate 
b   basic region 
bp   base pair 
BPB  bromphenolblue 
BSA   bovine serum albumin 
CBF  core binding factor 
CBP  CREB binding protein 
CDK  cyclin-dependent kinase 
cDNA  complementary DNA 
C/EBPs CCAAT/enhancer-binding proteins 
ChIP   chromatin immunoprecipitation 
Ci   curie 
CMV   Cytomegalie-virus 
CRH   cytokine receptor homologous 
CT  carboxy terminus  
ddH2O double destilled water 
DMEM Dulbecco´s modified Eagle medium 
DMSO dimethylsulfoxid 
DNA  desoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase  
dNTP   desoxynucleosidtriphosphate 
DOC   deoxycholate 
DPE   down core promoter element 
DTT  dithiothreitol 
E. coli  Escherichia coli 
ECL   enhanced chemiluminescence 
EDTA  ethlendiamintetraacetate 
FCS  fetal calf serum 
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FN   fibronectin 
G-CSF granulocyte colony stimulating factor 
HA  hemagglutenin 
HAT  histone-acetyltransferase 
HDAC  histone-deacetylase 
HEBS  hepes buffered saline 
HEPES N-2-hydroxyethyl-piperazin-N`-2-ethansulfone acid 
HLHLZip  helix-loop-helix leucine zipper 
hTERT human telomerase reverse transcriptase 
Ig  immunoglobulin 
JAK  Janus tyrosine kinase 
INR   initiator-element 
IPTG  b-D-isopropyl-thiogalactopyranoside 
kb   kilobase 
kDa  kilodalton 
KLF  Krueppel-like factor 
MAPK  mitogen activated protein kinase 
MED  multiple start site element downstream 
MEM  modified eagle medium 
Miz-1  Myc-interacting Zn-finger protein 1 
Mmip   Mad-member-interacting protein  
mRNA messenger RNA 
NCBI  National center of biotechnology information 
NLS   nuclear localization sequences 
OD  optic density 
ODC  ornithine decarboxylase 
ONPG o-nitrophenylgalactopyranoside 
PAGE  polyacrylamide gel electrophoresis 
PAH  paired amphipathic helix 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction  
PH   pleckstrin homology  
PI3K  phosphatidylinositol 3-kinase 
PI-3,4-P2 phosphatidylinositol-3,4-biphosphate  
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PIP3   phosphatidylinositol-3,4,5-triphosphate  
PKB  protein kinase B  
PMSF  phenylmethylsulfonylfluorid 
Pol  polymerase 
PTEN  phosphatase and tensin homologue deleted on chromosome 10 
RA  retinoic acid 
RNA  ribonucleic acid 
rpm  rotation per minute 
RPMI   Roswell Park Memorial Institute 
RT   room temperature 
SDS  sodium dodecylsulfate 
SHIP  SH2-containing inositol phosphatase 
SHP-1 SH2 domain-containing protein tyrosine phosphatase-1 
SID   Sin3-interactions domain 
SOCS  suppressors of cytokine signaling 
SP  Specificity protein 
STAT   the signal transducer and activator of transcription 
SUMO  small ubiquitin-related modifier  
SV40  simian virus 40 
TAD   transactivation domain 
TBP  TATA box binding protein 
TK   thymidinkinase 
TPA  12-O-tetradecanoylphorbol-13-acetate 
Tris   Tris-hydroxymethylaminomethan 
TSA   trichostatin A 
U   unit 
v/v   volume per volume proportion 
VEGF  vascular endothelial growth factor 
VitD3  1α, 25-dihydroxycholecalciferol 
w/v   weight per volume proportion 
WB  western blot 
wt   wild type 
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